Document jgarooxLbLBYr1bNZQKG1meoZ

Taft/ Taft Stettinius & Hollister LLP 425 Walnut Street, Suite 1800/Cincinnati, OH 45202-3957 /Tel: 513.381.2838 / Fax: 513.381.0205 /www.taftlaw.com Cincinnati / Cleveland / Columbus / Dayton / Indianapolis / Northern Kentucky / Phoenix / Beijing A.R o b e r t B il o t t 513.357.9638 bilott@taftlaw.com Ai-zx-z& y February 2, 2009 TSCA Confidential Business Information Center (7407M) EPA East - Room 6428, Attn: Section 8(e) & FYI U.S. Environmental Protection Agency 1200 Pennsylvania Avenue, NW Washington, DC 20460-0001 C3 Z-t ~-.'2 '7Q "t cS * Zl fr.. --nC 03 c 0on Re: Submission To TSCA 8(e)/FYI Database Re: PFOA/PFOS To TSCA 8(e)/FYI Database: W e are hereby providing the following information for inclusion in the TSCA 8(e)/ FYI databases with respect to PFOA/PFOS: 1. C-8 Science Panel Status Report, "Association of Perfluorooctanic Acid (PFOA) and Perfluorooctanesulfonate (PFOS) with Uric Acid Among Adults with Elevated Community Exposure to PFOA" (Jan. 23, 2009); 2. Fei, C., et al, "Maternal Levels of Perfluorinated Chemicals and Subfecundity," 1 Hum. Reprod. 1-6 (Jan. 28, 2009); 3. West Virginia University, "C-8 Health Project Results: C-8 and Other Clinical Conditions and Diagnoses" (Jan. 2009); and 4. West Virginia University, "C-8 Health Project Results: C-8 and Other Laboratory Values" (Tabular Format) (Jan. 2009). ! I i i I iil h h ; RAB:mdm Enclosures 11322984.1 0o* T**BMocai o o*a **1* 00 Status report: Association of perfluorooctanic acid (PFOA) and perfluoroctanesulfonate (PFOS) with uric acid among adults with elevated community exposure to PFOA The C8 Science Panel (Kyle Steenland, Tony Fletcher, David Savitz) January 23,2009 This report summarizes the findings relating PFOA (C8) and PFOS (C8S) to levels of uric acid in the serum of the participants in the C8 Health Project, which was carried out in 2005-2006 in the Mid-Ohio Valley. A full report of these findings will be submitted to a peer-reviewed scientific journal. Background: Perfluorooctanoic acid (PFOA, also known at C8) and perfhioroctanesulfonte (PFOS, also known at C8S) are compounds which do not occur in nature but have been widely used in chemical production since WWII, and persist indefinitely in the environment. They are present in the serum ofmost Americans at median (50thpercentile) levels of 4 ng/ml (nanogram/milliter) and 21 ng/ml, respectively, and also present in the serum of residents of many other countries. PFOA has been associated with elevated uric acid in one study of exposed workers, but not previously studied in a general population. Uric acid is a risk factor for hypertension and possibly for other cardiovascular disease. Methods: We conducted a cross sectional study to examine the association between PFOA and PFOS and uric acid in the serum among 55,388 community residents age 18 and older in Ohio and West Virginia, who lived or worked in six water districts contaminated with PFOA from a chemical plant. All these residents participated in the C8 Health Project in 2005-2006. At that time they gave blood, which was used to measure both PFOA and uric acid in the serum (the liquid clear part of the blood after blood cells have been taken out). We compared their levels of uric acid in relation to levels of C8 via multiple regression techniques, while adjusting for other variables which could influence uric acid. Results: The median (50thpercentile) of uric acid level in the population was 5.5 mg/dl (milligram/deciliter). The median level of PFOA was 30 ng/ml, while the median level of PFOS was 20 ng/ml. Both PFOA and PFOS were significantly associated with increases in uric acid levels, with an increase of 0.2-0.3 mg/dl in uric acid associated with an increase from the lowest to highest decile (each decile represents 10% of the population) of either PFOA or PFOS. The risk of excessive uric acid (defined as >6 mg/dl in women, >6.8mg/dl in men) increased modestly with increasing quartile of each of the two chemicals; the ratios of risk for each quartile versus the first quartile were 1.00, 1.24 (95% confidence interval 1.16-1.32), 1.34 (95% confidence interval 1.26-1.43), and 1.38 (95% confidence interval 1.30-1.47) for PFOA and 1.00, 1.06 (95% confidence interval 0.99-1.12), 1.17 (95% confidence interval 1.10-1.24), and 1.25 (95% confidence interval 1.17-1.33) for PFOS. Conclusion: Higher serum levels of both PFOA and PFOS were associated with a higher risk of excessive uric acid in the blood. However, because of the fact that uric acid and PFOA/PFOS were measured at the same time, we cannot know if an increase in either PFOA or PFOS would lead to an increase in uric acid. Other possibilities include that both uric acid and these two chemicals increase in relation to some other unknown chemical in the blood, or even that an increase in uric acid in fact causes an increase in PFOA or PFOS for unknown reasons. Therefore no firm conclusions about a causal relationship between PFOA or PFOS and uric acid can be drawn from these findings. i1 Hum. Reprod. Advance A cce ss published January 28, 2009 Hum an Reproduction, V o l.l, N o.I pp. 1-6, 2009 d o i: 10 . 1 09 3 /hu m rep /d en 49 0 P-6 Maternal levels of perfluorinated chemicals and subfecundity Chunyuan F e i1'5, Joseph K. M cLaughlin2'3, Loren Lipw orth2*3, and Jorn O lse n 1'4 1Department of Epidemiology, School o f Public Health, University of California - Los Angeles, P O Box 951772, 7 1-254 C H S , 650 Charles E. Young D rive South, Los Angeles, C A 90095-1772, USA international Epidemiology Institute, 1455 Research Boulevard, Rockville, M D 20850, U S A V and erbilt University Medical Center, Vanderbilt-lngram Cancer Center, Nashville, T N 37232, U SA in stitu te o f Public Health, University of Aarhus, Vennelyst Boulevard 6, D K 8000 Aarhus C , Denmark C o rresp o nd en ce address. T e l: + I-3IO -825-5373; Fax: +1-310-206-6039; E-mail: cfei@ucla.edu B A C K G R O U N D : Perfluorooctanoate (P F O A ) and perfluorooctane sulfonate (P FO S ) are ubiquitous m an-m ade com pounds th at are poss ible horm onal d isru p te rs. W e exam ined w h eth er exp osure to these com poundsm ay decrease fecundity in' hum ans. M E T H O D S : Plasm a levels o f PFO S and P FO A w ere m easured a t w eeks 4 - 1 4 o f pregnancy among 1240 w om en from th e D anish N ational B irth C o h o rt recru ited from 1996 to 20 02 . Fo r this pregnancy, w om en reported tim e to pregnancy (T T P ) in five categories (< I , I - 2 , 3 - 5 , 6 - 1 2 and > 12 m onths). In fertility w as defined as having a T T P o f > 12 m onths o r received in fertility treatm ent to establish this pregnancy. R E S U L T S : Longer T T P w as associated w ith higher m aternal levels o f P FO A and PFO S (P < 0 .0 0 1 ). Com pared w ith w om en in the low est exp osure q u artile, th e adjusted odds o f in fertility increased by 7 0 - 13 4 and 60-15456 among w om en in the 'higher three q u artiles o f PFO S and P F O A , resp ectively. Fecundity odds ratio s (F O R s) w ere also estim ated using C o x discrete-tim e m odels. T h e adjusted FO R s w e re virtu ally identical fo r w o m en iin ^ e th re e highest exp osure .groups o f P fi> S (1-OR =s 3pL 0 .6 7 and 0 .7 4 , resp ectively) com pared w ith the lo w est q u artile. A ftnear-Wce trend w as observed fo r P F O A (F O R = 0 .7 2 , 0 .7 3 and 0 .6 0 fo r th re e highest quartiles versus lo w est q u artile). W h en all quartiles w ere included'm a likelihood ratio te st, the tren ds w eresig m fican t fo r PFO S and P F O A (P = 0 .00 2 and P C 0 .0 0 I, resp ectively). C O N C LU S IO N S : Th ese findings suggest th at P FO A and PFO S exp osure at plasm a levels seen in the general population m ay reduce fecund ity; such exp osure levels are com m on in developed countries. K e y w o rd s: m aternal blood / tim e to pregnancy / fecundity / perfluorooctanoate / perfluorooctane sulfonate Introduction Perfluorooctane sulfonate (P FO S) and perfluorooctanoate (P FO A ) belong to a class o f perfluorinated chem icals (P FC s) th at are w idely used in m any consum er products (p ap er w rap s, fire-fighting foam s, pesticid es, te xtile s including clothing, up holstery, carpets and personal care products) and in m anufacturing processes (industrial surfactants and em u lsifiers). Th ey are persistent in the environm ent and have been detected in w ild life and hum ans around the w orld (G iesy and Kannan, 20 01 ; Kannan et o f, 2004; Apelberg et o f, 2007; Calafat et a i, 20 07 ; Fei et o f, 20 07 ). Th ey w ere considered biologically inac tive w hen first com m ercially introduced in the I9 5 0 's, but anim al studies o f P FO A and PFO S have since indicated to xic effects on the liv e r, im m une system and developm ental and reproductive organs (Kennedy et o f, 20 04 ; Lau et o f, 20 04 , 20 07 ). P FO A and PFO S may affect sex horm one hom eostasis, and have been associated w ith increased incidence o f fetal resorptions and pregnancy loss in anim als (C ase et o f, 2001; Butenhoff et o f, 2004; Lau et a/,, 2006; W o lf et o f, 20 07 ). In recent decades, a rem arkable decline in fertility rates has been observed in developed co untries, w hich can largely be explained by social changes in desired fam ily sizes and b etter contraceptive m ethods, but m ay also in part be attributed to reduced fecundity, the biological capacity to reproduce (O lsen and Rachootin, 20 03 ). In the U SA , 2% o f w om en o f reproductive age had an infertility-related m edical appointm ent w ithin the previous year, and 8% had an infertility-related m edical visit at som e point in the past (C en ters fo r D isease C o n tro l and Prevention (C D C ), 20 08 ). Infertility is associated w ith psychological stress and anxiety fo r wom en and couples, and w ith adverse birth outcom es o r diseases (Z hu et al,, 2007; Jensen et a/., 20 08 ), and treatm ent carries financial burdens fo r individuals and fo r so c ie ty . Environm ental pollutants, such as polychlorinated biphenyls, pesti cides and o th er chem icals (Taskinen et a/., 1999; Law et o f, 20 05 ), T h e A u th o r 2 00 9. Published by O xfo rd U n iversity P ress on behalf o f th e European Society o f H um an R eprod uction and Em bryology. A ll rights reserved . F o r P e rm issio n s, p lease em ail: jo u rn als.perrn ission5@ oxford jou rnals.o rg . !I p.7 2 Fei et al. have been linked to subfecundity. In a previous paper (Fei et al., 20 07 ), w e reported that m aternal PFO S and P FO A levels w ere inversely related to p arity, perhaps due to fetal uptake during pregnancy o r excretio n by breast m ilk, but this association could also be explained by a link betw een exp osure to PFO S o r P FO A and subfecundity. W e used data from the D anish N ational Birth C o h o rt (D N B C ) to assess w h eth er m aternal plasm a PFO S and P FO A levels, m easured in early pregnancy, w e re associated w ith a longer tim e to pregnancy (T T P ), a m easure th at has been used to estim ate fecundity in epidem iologic studies fo r m ore than 25 years (Rachootin and O lsen , 1982). Materials and Methods The wom en w ere enrolled into the D N B C , a nationwide follow-up study o f alm ost 100 000 children and their m others. More details about the cohort have been presented elsewhere (O lsen et al., 2001). Briefly, preg nant wom en w ere recruited through th eir general practitioners around weeks 6 -1 2 o f gestation. Approxim ately 50% o f all general practitioners in Denm ark participated in the study, and approxim ately 60% of invited wom en accepted the invitation to participate. Self-reported data w ere col lected by com puter-assisted telephone interviews tw ice during pregnancy and tw ice after birth. A study biobank was set up, consisting of two m aternal blood samples taken during pregnancy, and one umbilical cord blood sample obtained shortly after birth. W e measured plasma PFO A and PFOS levels in a subset o f D N BC par ticipants. Among all participants (n = 43 045) who provided the first m aternal blood sample, gave birth to a single live bom child without con genital m alform ation, and completed all four telephone interviews, w e ran domly selected 1400 wom en. Detailed information about sampling has been described elsewhere (Fei et al., 2007). W e excluded 160 with unplanned pregnancies o r unknown T T P . Altogether, 1240 women were included in our main analyses. W ritten informed consent was obtained from all participants at recruit m ent. Th e U C LA O ffice fo r Protection o f Research Subjects (Reference N o. 06-08-023-01) and the Danish Data Protection Agency (Reference N o. j.N r 2006-41-6324) approved the study protocol. Tim e to pregnancy In the first interview (at approxim ately 12 weeks o f gestation), women w ere asked if their pregnancy was planned, partly planned o r not planned. A ll except those responding 'not planned' w ere further asked, 'Fo r how long did you try to get pregnant before you succeeded?' followed by five fixed answering categories of T T P : got pregnant immediately (i.e . < 1 m onths), 1 -2 , 3 - 5 , 6 -1 2 and > l2m o nth s. Infertility was defined as having a T T P o f > 12 months o r infertility treatm ent to establish the current pregnancy. PFOA and PFOS exposure W e used the m aternal blood samples taken at the first antenatal visit (w eeks 4 -1 4 o f pregnancy) for this study. Concentrations of PFO S and PFO A in plasma w ere measured by high perform ance liquid chromatography/tandem mass spectrom etry at the 3M Toxicology Laboratory (Ehresm an et a i, 2007). Stable labeled analogs of PFOS ( I8 0 2 PFOS) and PFO A ( 13C2 PFO A ) were used in extraction procedures, and the extractions w ere perform ed using solid phase extraction techniques and based on 100 p.1 o f plasma. A ll values w ere above LLO Q (the lower lim it o f quantification: I ng/m l), except one PFO A value that was assigned a value o f half the LLO Q . Further details about the analysis methods w ere given in our earlier report (Fei et a i, 2007). Th e laboratory was blinded to any inform ation on the pregnant wom en. Statistical analysis PFO A and PFOS levels w ere analyzed as continuous variables and were also categorized a priori into quartiles using the lowest quartile as the reference group. W e first used logistic regression to estim ate the odds ratios (O R s) of infertility fo r wom en who w ere exposed to higher levels of PFO A o r PFOS compared w ith the reference level. Fecundity odds ratios (FO R s) were then estim ated using the C ox model modified for dis crete time data (Allison 1995). Approxim ate median numbers of months (i.e . 1, 2, 4 and 9) w ere assigned to the first four reported categories of T T P . T T P was censored at the 13th month if women had a T T P > 12 months o r received infertility treatm ent for this pregnancy (n = 201). In our study, FO Rs measure the odds of a successful conception for women who had higher levels o f PFO A o r PFOS compared w ith the refer ence levels within a given calendar month, given that the women did not become pregnant in the previous month. FO Rs < I therefore indicate decreased fecundity and a longer T T P . A value of P < 0.05 was considered statistically significant. Potential confounders included maternal age at delivery, parity, pre pregnancy body mass index (BM I), maternal socio-occupational status, paternal education, paternal age and alcohol consumption before preg nancy. Age at m enarche, irregular menstrual periods, history o f spon taneous m iscarriages, abdominal diseases (e.g. endom etriosis, pain), paternal occupation and gestational weeks at blood drawing w ere also considered, but w ere not included in the final models as they had little effect on the estimated associations. Information on smoking and coffee consumption w ere only reported after pregnancy and women w ith T T P > 12 months w ere m ore likely to have stopped smoking; furtherm ore, adjustment for these variables did not change the associations between PFO A o r PFOS and the outcom e, and w ere therefore not included in the models. Results H alf o f the wom en becam e pregnant w ithin the first 2 m onths o f trying, w hile 379 (30% ) had a T T P o f > 6 m onths, 188 o f whom had a T T P o f > 12 m onths. Th e average age o f the w om en was 30 .6 years and 15% w ere above 35 years o f age at delivery. A bout half o f the w om en w ere expecting th eir first child (Tab le I), and one-third w ere overw eight o r obese. Eighteen p e r cen t had a history o f spontaneous m iscarriages and 14% reported experiencing irregular m enstrual cycles p rio r to this pregnancy. T h e median plasm a P FO A and PFO S levels among the planned o r partly planned pregnancies w ere 5.3 ng/m l [interquartile (IQ R ): 4 .0 , 7 .0 ] and 33 .7 ng/m l (IQ R : 2 6 .6 , 4 3 .5 ), respectively. A s previously reported (Fei et a i, 20 07 ), PFO S and PFO A levels decreased w ith increasing age o r parity and w ith decreasing pre-pregnancy BM I. P FO A levels w ere associated w ith irregular m enstrual periods (9.0% in the low est quartile versus 15.0% in the upper th ree q u artiles), as w ell as PFO S ( 11.6% in the low est quartile versus 14.2% in the upper three q u artiles). Com pared w ith wom en w ho got pregnant in the first 6 m onths o f w aiting tim e, wom en w ho had a longer T T P had higher PFO A and PFO S levels (P < 0.001 fo r both), and they w ere m ore likely to be o ld er, o f m iddle socio-occupational status, and to have a history o f spontaneous m iscarriages o r irregular men strual cycles (Table I). Th o se w ith younger partners o r partners w ith higher education levels had a sh o rter T T P . Th e proportion o f w om en w ith T T P > 12 m onths (in fertility) w as higher in the higher th ree quartiles o f PFO A and PFO S versus the low est quartile (Tab le II). W e estim ated that the odds o f infertility ;i p.8 Perfluorinated chem icals and tim e to pregnancy 3 Table I Characteristics ofstudy subjects and TTP among women with planned pregnancy* W o m e n w ith p la n n e d p re g n a n c y (n = 1240)% <6 m on ths (n = 861)% 6 -1 2 m on ths ( n = 191)% PFO S, ng/m lb 35.5 12.8 PFO A , ng/m lb 5.6 2.6 Maternal age at delivery < 2 5 years 7.8 2 5 -2 9 years 40.0 3 0 -3 4 years 37.0 > 35 years 15.2 Parity 0 44.7 1 36.3 > 2 19.0 Pne-pregnancy BMI < 18.5 k g /m 2 4.2 1 8.5-24.9 kg/m 2 66.3 2 5 .0 -2 9 .9 kg/m2 22.3 > 3 0.0 kg/m 2 7.2 Maternal SES Higher 51.9 M iddle 40.2 Lo w er 7.9 Alcohol consum ption before pregnancy (drinks/w eek) 0 to < 1 22.0 1 - 1 .5 24.0 2 - 3 22.0 > 3 32.0 Smoking in early pregnancy Yes 22.7 N o 77.3 H istory o f spontaneous miscarriages N o 82.0 Y e s 18.0 Irregular m enstrual periods N o 86.4 Y e s 13.6 Paternal age < 3 0 years 29.4 3 0 -3 4 years 39.3 3 5 -3 9 years 23.1 > 4 0 years 8.2 Paternal education Lo w er 20.2 M iddle 33.9 H ig h e r 41.6 O ther o r unknown 4.3 3 4 .6 12.7 5.4 2.2 8.8 42.1 37.0 12.1 41.9 39.4 18.7 3.8 67.9 21.9 6.3 54.2 37.4 8.4 20.8 22.7 23.3 33.3 22.5 77.5 85.2 14.8 88.2 11.8 32.3 4 1 .0 20.1 6.7 19.2 31.7 45.1 4.1 3 6 .6 12.5 6.0 3.4 8.4 39.3 35.1 17.3 4 9 .2 32.5 18.3 5.9 6 1 .0 24.6 8.6 45.3 4 7 .4 7 .4 23.7 2 2 .6 20.5 33.2 27.2 72.8 74.9 25.1 8 7 .9 12.1 28.4 35.8 24.7 11.0 24.6 36.1 34.6 4 .7 ty,' M issing d ata: m aternal age a t d elivery (n = I) . pre-pregnancy BM I (n = 2 7 ). m a t e t r r is o d o - ^ c u p a t ^ con sum p tion b efo re p re p o n e / (n = 3 ), p atern al age (n = t btiata are m ean S D . P F O A , p e rflu o ro o cta iw a ^ > 12 m o n th s (n = 188)% 38.3 13.0 6.3 2.7 PFO A (n g /m l)b _ _ PFO S (n g /m l)b _ 2.1 31.4 39.4 27.1 6.1 1.9 6.1 2.8 5.2 2.3 5.2 2.4 3 8 .0 10.9 37.1 12.6 3 4 .2 13.3 33.2 12.5 5 4 .8 3 3 .0 12.2 6.7 2.7 4.8 2.0 4.6 2.2 37.8 12.7 3 3 .7 12.7 3 3 .5 12.3 4.3 64.2 21.4 10.2 5.2 2 .1 5.6 2.7 5.7 2.3 6.1 2.6 32.9 13.8 3 5 .0 12.8 3 6 .7 11.8 38.8 13.8 4 7 .6 4 6 .0 6 .4 5.6 2.4 5.7 2.8 5.6 2.2 34.2 12.5 37.1 12.8 3 6 .9 13.8 2 5 .7 31.6 17.6 25.1 5.3 2.2 5.8 2.4 5.5 2.2 5.9 3 .1 35.4 12.4 3 7 .0 12.8 3 5 .7 13.1 3 4 .4 12.8 19.0 8 1 .0 74.3 2 5 .7 77.1 2 2 .9 5.6 2.3 5.6 2.6 3 4 .4 11.7 35.8 13.1 5.7 2.6 5.3 2.2 35.6 12.7 35.1 13.4 5.6 2.6 5.8 2.0 35.4 13.0 3 6 .0 11.6 17.1 35.3 35.3 12.3 20.7 41.5 3 3 .0 4 .8 6.2 2.4 5.5 2.8 5.3 2.2 5.2 2.5 3 8 .0 12.3 3 5 .0 12.9 34.3 13.4 33.3 + 11.3 5.7 2.1 5.9 3.0 5.4 2.4 5.7 2.6 3 8 .2 + 12.4 37.5 + 12.8 32.8 12.5 3 3 .4 12.9 spon tan eou s m iscarriag es (n = I) . alcohol fo n ate. TI P-9 Fei et al. T(nagb/mlel)IIinEesatrimlyapteredgOnaRncfoyr2infertility (TTP >12 months) and FOR according to plasma concentrations of PFOS or PFOA Exp o su re N o . o f p la n n e d p re g n a n cy In fe rtility P er cent O R (95% C l) b F O R (95% C l) c PFOS (ng/ml) 6.4 -2 6 .0 2 6 .1 -3 3 .3 3 3 .4 -4 3 .2 >43.3 P-value for trend'1 PFOA (ng/m l) < LLO Q -3.91 3 .9 1 -5 .2 0 5 .2 1 -6 .9 6 > 6.97 P-value for trend11 293 305 317 317 293 308 315 316 10.6 15.4 19.5 18.6 8.9 18.2 15.5 21.5 1.00 1 .7 0 (1 .0 1 ,2 .8 6 ) 2.34 (1.40, 3.89) 1 .7 7 (1 .0 6 ,2 .9 5 ) 0.025 1.00 2.06 (1.22, 3.51) 1.60 (0.93, 2.78) 2.54 (1.47, 4.39) 0.006 1.00 0.70 (0.56, 0.87) 0.67 (0.53, 0.84) 0.74 (0.58, 0.93) 0.002 1.00 0.72 (0.57, 0.90) 0.73 (0.58, 0.92) 0.60 (0.47, 0.76) <0.001 T > e estimateswere adjustedfor maternal age at defivery, parity, pre-pregnancy BMl, maternal SES, alcohol consumption before pregnancy.patemal age, and paternal education; seven women (from a total of l2d<J) were excluded because of missing data on covariates; bLo0stic regression; 'C o x discrete-time model; *The P-rJalues for trend tests of FORs w ere given fo r the four-quartife comparison of PFO A and PFOS leveb using a likelihood ratio te s t C l, confidence interval; FO R , fecundity odds ratios; LLO Q . lower limit of quantification. Increased by 7 0 --134% fo r w om en in each o f the higher exposure cat egories o f P FO S, and 6 0 - 154% fo r wom en In each o f the higher exp osure categories o f P FO A , com pared w ith the low est quartile. W om en w ho w ere exposed to higher levels o f P FO A o r PFO S had a longer T T P ; the adjusted FO R s w ere 0 .7 0 , 0.67 and 0 .74 fo r the top th ree q u artiles o f PFO S and 0 .7 2 , 0.73 and 0 .6 0 fo r the top th re e q uartiles o f P FO A (versus the low est quartile) (Tab le II). W h en all q u artiles w ere included in a likelihood ratio te st, the tren ds w ere significant fo r PFO S and P FO A (P = 0.0 0 2 and < 0 .0 0 1 , resp ectively). W o m en w h o w e re carrying unplanned pregnancies had lo w er PFC levels. Th e m edian level w as 4 .8 ng/m l (IQ R : 3 .5 , 6 .6 ) fo r P FO A and 3 0 .0 ng/m l (IQ R : 2 6 .6 , 4 3 .5 ) fo r P FO S . Th ey w ere o f younger age (< 2 5 years) o r m uch o ld e r (> 3 5 y e ars), m ore often parous and o f lo w er socio-occupational status. Th ey w ere less likely to take contra cep tive pills and to d rink alcohol before pregnancy, but m ore likely to sm oke in early pregnancy. Including these w om en as having a T T P o f < I m onth' strengthened the observed associations (data not show n). O n ly including w om en w ith regular m enstrual periods slightly lessened the association (d ata no t show n). Discussion T o o u r know ledge, this is the first study to assess the associations betw een P FO A and PFO S plasm a levels and T T P in hum ans. Higher m aternal P F O A and PFO S levels m easured in early pregnancy w ere found to be associated w ith longer I IP . Th e odds o f a conception leading to a recognized pregnancy w ere reduced fo r wom en w ho w ere exposed to PFO S and P FO A above the low est q uartile, and the m agnitude o f the reduction in fecundity was sim ilar fo r the three higher qu artiles. T h e exposure tim e w indow o f interest is at the start o f pregnancy planning, but our exposure data w ere taken at 4 - 14 w eeks gestation. P FO A and PFO S levels w ere, how ever, rath er stable o ver pregnancy (Fei et al., 20 07 ). W e assum e that o u r exposure assessm ent reflects the exp osure level during the entire pregnancy planning tim e period. Inform ation on T T P w as obtained during the first trim ester when w om en should be able to recall this w ith reasonable accuracy (joffe et al., 20 05 ). W e further provided five response categories in o rd er to facilitate valid recall, at the expense o f precision. D ifferential recall by wom en according to PFC levels is unlikely to be a problem in o u r study since the exposure levels w ere unknown to them . M aternal age, paternal age and paternal education substantially changed the associations betw een PFO S and T T P , w hile parity and paternal education w ere the m ost influential confounders in the analy sis o f P FO A . W e did not have inform ation on som e im portant deter m inants o f T T P , including frequency and tim ing o f intercourse, and sperm quality. Sperm quality could potentially contribute to the associ ations betw een m aternal PFC levels and T T P , if these com pounds im pact sperm quality and if P FC levels in m ale and fem ale partners are sim ilar, w hich is likely to som e extent since the couples may share som e aspects o f lifestyle and around 99% subjects in this sub cohort had a spouse o r p artner. Adjustm ent fo r paternal occupation did not change the estim ates. Th e re are several potential lim itations o f o u r study. First, w e studied T T P o f pregnancies w hich led to the birth o f a child, lim iting conclusions that can be draw n regarding wom en w ho w ere unable to get pregnant, even after infertility treatm ent. O nly couples who planned o r partly planned th eir pregnancy can rep o rt a T T P . N inety p er cent o f the wom en planned o r partly planned th eir preg nancy in o u r study. Selection bias resulting from exclusion o f fertile w om en w ho did not plan th eir pregnancy is possible, and o u r data show ed that the associations betw een PFC levels and longer T T P Perfluorinated chemicals and time to pregnancy 5 w e re stronger afte r inclusion o f unplanned pregnancies in the a n a ly s e s. T h e biological m echanism by w hich exp osure to PFO S and PFO A m ay reduce fecundity is unknow n. PFC s m ay interfere w ith hypothala m ic -p itu ita ry -o v a ria n regulation, possibly causing irreg ular m enstrual cycle s, delayed ovulation o r early abortions not recognized by the m other. In this stud y, w e found sim ilarly higher proportions o f w om en reporting irreg ular m enstrual periods in the upper th ree quar tile s o f PFC s com pared w ith the lo w est. Sim ilarly, exposure to PFO S can reduce the num ber o f regular estrous cycles in rats (A ustin et a/., 2 0 0 3 ). Although the doses adm inistered to rats w ere higher than the levels found in o u r stud y, but close to those found in occupationally exposed hum an populations (O lsen et a/., 1999), the findings o f A u stin et al. (2 0 0 3 ) m ay not apply to m an, since the rodent estrous cycle is not an ideal m odel fo r the hum an cycle and the half-lives o f th ese chem icals in humans greatly differ from those in anim als. Increased levels o f estrogen a n d /o r decreased levels o f testosterone have also been found in m ale rats given o ral doses o f P FO A at 2 m g /kg /d ay o r higher (C o o k et al., 1992; Biegel et al., 1995; Liu et al., 1996; M artin et al., 20 07 ). A dose o f 3 m g/kg/day is approxi m ately equivalent to 4000 ng/m l in rat serum , w hich is slightly higher than levels observed in occupationally exposed populations (B utenhoff et al., 2 0 0 4 ), but fem ale rats w ere not studied as often as m ale rats in th e studies of P FO A . A bnorm al horm one levels may have an im pact on in fertility, and results from several anim al studies, although not all, show ed that exp osure to P FO A o r PFO S increased the incidence o f spontaneous m iscarriages (C ase et al., 2001; Butenhoff et al., 20 04 ; Lau et al., 20 06 ; W o lf et a l, 20 07 ). In conclusion, o u r data suggest th at exp osure to P FO A and PFO S at levels found in the general population m ay increase T T P . W h e th e r our resu lts w ill add PFC s to the list o f risk factors fo r subfecundity rem ains to be seen, but P FC s m ay explain som e o f the fertility differences seen am ong different populations in developed countries. Authors' contributions C .F . designed the stud y, analyzed and interp reted the data, drafted the paper. J.O . m onitored each step o f the study, designed the study, guided analysis and interp retation o f the data, and revised the p a p er.J.K .M . designed the study, interp reted the data and revised the paper. L .L . interp reted the data and revised the paper. Acknowledgements Th anks are extended to the 3M Toxicolog y Laboratory led by David J. Ehresm an. Th ey perform ed all laboratory analyses. Funding T h e original study w as supported by the International Epidem iology Institute (IE I), w hich received a funding grant from the 3M Com pany. Th e 3M Com pany has no control o ver the design, data analysis and in terp retatio n o r w riting o f this study. J.K .M . and L .L . w ere em ployed by IE I. J.O . and C .F . independently w o rk at the U n iversity o f C alifornia, Los Angeles and have no com peting financial interest. References Allison PD . Survival Analysis using SAS: A Practical Guide. C ary, N C : SAS Institute Press, 1995, 134-136. Apelberg BJ, W itte r FR, Herbstman JB, Calafat AM , Halden RU , Needham LL, Goldm an LR . C ord serum concentrations of perfluorooctane sulfonate (PFO S) and perfluorooctanoate (PFO A ) in relation to weight and size at birth. Environ Health Perspea 2007; 1 1 5 :1 6 7 0 -1 6 7 6 . Austin ME, Kasturi BS, Barber M, Karman K , MohanKumar PS, MohanKumar SM. Neuroendocrine effects of perfluorooctane sulfonate in rats. Environ Health Perspect 2003;111:1485-1489. Biegel LB, Liu R C , H urtt M E, Cook JC . Effects of ammonium perfluorooctanoate on Leydig cell function: in vitro, in vivo and ex vivo studies. Toxicol Appl Pharmacol 1995;134:18-25. Butenhoff JL, Kennedy G L Jr, Fram e SR, O 'Connor JC , York R G . The reproductive toxicology o f ammonium perfluorooctanoate (A PFO ) in the rat. Toxicology 2004; 19 6 :9 5 - 116. Calafat AM , W ong LY, Kuklenyik Z , Reidy JA , Needham LL. Polyfluoroalkyl chem icals in the U .S. population: data from the National Health and N utrition Examination Survey (N H A N ES) 2003 2004 and comparisons to N H AN ES 1999-2000. Environ Health Perspea 2007; 115 :15 9 6 - 1602. Case M T, Yo rk R G , Christian MS. Rat and rabbit oral developmental toxicology studies w ith tw o perfluorinated compounds. Int J Toxicol 2 0 0 1 ;2 0 :1 0 1 -1 0 9 . Centers for Disease Control and Prevention (C D C ). Assisted Reproductive Technology. 2008; http://w w w .cdc.gov/ART/2008(date last accessed, 6 May 2008). Cook JC , M urray SM, Fram e SR, H urtt ME. Induction of Leydig cell adenomas by ammonium perfluorooctanoate: a possible endocrinerelated mechanism. Toxicol Appl Pharmacol I9 9 2 ;l 13:209-217. Ehresman DJ, Froehlkh JW , Olsen G W , Chang SC , ButenhoffJL. Comparison of human whole blood, plasma, and serum matrices for the determination of perfluorooctanesulfonate (PFO S), perfluorooctanoate (P FO A ), and other fluorochemicals. Environ Res 2007; 10 3 :17 6 - 184. Fei C Y , McLaughlin JK , Tarone RE, O lsen J. Perfluorinated chemicals and fetal growth: a study within the Danish National Birth C ohort. Environ Health Perspea 2007; 115 :16 7 7 - 1682. Giesy JP, Kannan K . Global distribution of perfluorooctane sulfonate in w ildlife. Environ Sci Technol 2001;35:1339-1342. Jensen A , Sharif H , O lsen JH , Kjaer SK. Risk of breast cancer and gynecologic cancers in a large population of nearly 50,000 infertile Danish wom en. Am J Epidemiol 20 08 ;1 68 :49 -57 . Joffe M, Key J, Best N , Keiding N , Scheike T , Jensen T K . Studying time to pregnancy by use o f a retrospective design. Am j Epidemiol. 2005; 1 6 2 :1 1 5 -1 2 4 . Kannan K . Corsolini S, Falandysz J, Fillmann G , Kum ar KS, Loganathan BG, Mohd M A, O livero J, Van W ouwe N , Yang JH et al. Perfluorooctanesulfonate and related fluorochem icals in human blood from several countries. Environ Sci Technol 2004;38:4489-4495. Kennedy G L Jr, Butenhoff JL, O lsen G W , O 'Connor JC , Seacat AM , Perkins R G , Biegel LB, Murphy SR, Farrar D G . The toxicology of perfluorooctanoate. Ort Rev Toxicol 2004;34:351-384. Lau C , Butenhoff JL, Rogers JM. The developmental toxicity of perfluoroalkyl acids and their derivatives. Toxicol Appl Pharmacol 2004; 1 9 8 :2 3 1 -2 4 1 . Lau C , Thibodeaux JR , Hanson R G , N arotsky M G, Rogers JM, Lindstrom A B , Strynar MJ. Effects of perfluorooctanoic acid exposure during pregnancy in the mouse. Toxicol Sd 20 06;90:510-518. it ft p . 11 ~'6 Fei et of. Lau C , Anitole K , Hodes C , Lai D , Pfahles-Hutchens A , Seed J. Perfluoroalkyl acids: a review of monitoring and toxicological findings. Toxicol Sci 20 07 ;9 9:366 -39 4. Law D C . Klebanoff M A, Brock JW , Dunson D B, Longnecker MP. Maternal serum levels o f polychlorinated biphenyls and l,l-d ichloro-2,2-b is (p-chlorophenyl)ethylene (D D E) and tim e to pregnancy. Am ] Epidemiol 2 0 0 5 ;1 62 :52 3-5 32 . Liu R C , H u rtt ME, C ook JC , Biegel LB. Effect of the peroxisom e proliferators, ammonium perfluorooctanoate (C 8 ), on hepatic arom atase activity in adult male C ri: C D BR (C D ) rats. Fundam Appl Toxicol 1996;30:220-228. M artin M T, Brennan RJ, Hu W , Ayanoglu E . Lau C , Ren H , W ood C R , C orton JC , Kavlock RJ, D ix D J. Toxicogenom ic study o f triazole fungicides and perfluoroalkyl acids in rat livers predicts toxicity and categorizes chem icals based on mechanisms of toxicity. Toxicol Sci 20 0 7 ;9 7 :5 9 5 -6 1 3 . O lsen J, Rachootin P. Invited com m entary: Monitoring fecundity over tim e-- if w e do it, then let's do it right. Am J Epidemiol 2003; 15 7 :9 4 -9 7 . O lsen G W , Burris JM , Mandel JH , Zobel LR . Serum perfluorooctane sulfonate and hepatic and lipid clinical chem istry tests in fluorochem ical production em ployees. J Occup Environ M ed 1999; 4 1 :7 9 9 -8 0 6 . O lsen J, Melbye M, O lsen SF, Sorensen T I, Aaby P, Andersen AM , Taxbol D , Hansen K D . Juhl M, Schow T B et al. The Danish National Birth Cohort-- its background, structure and aim. Scand J Public Health 20 01;29:300-307. Rachootin P, O lsen J. Prevalence and socioeconom ic correlates of subfecundity and spontaneous abortion in Denm ark. Int J Epidemiol 1 9 8 2 ;1 1 :2 4 5 -2 4 9 . Taskinen H K, Kyyrnen P, Sallmn M, Virtanen SV, Liukkonen TA , Huida O , Lindbohm ML, Anttila A . Reduced fertility among female wood w orkers exposed to formaldehyde. Am ] Ind Med. 1999; 36 .2 0 6 -2 1 2 . W o lf C J, Fenton SE, Schmid JE, Calafat AM , Kuklenyik Z , Bryant X A , Thibodeaux J, Das KP, W hite SS, Lau C S et al. Developmental toxicity of perfluorooctanoic acid in the CD-1 mouse after cross-foster and restricted gestational exposures. Toxicol Sci 2007; 9 5 :4 62 -47 3. Zhu JL, O bel C , Hamm er Bech B, O lsen J, Basso O . Infertility, infertility treatm ent, and fetal growth restriction. Obstet Gynecol 2007; 1 1 0 :1 3 2 6 -1 3 3 4 . Submitted on September 12, 2008; resubmitted on November 7, 2008; accepted on December 18, 2008 WVU :: School o f Medicine :: Community Medicine :: C8 P*g3 o f2 Site Map C8 Home What is C8 What's New? C8 Health Project Settlement Details Brookmar Project Team Science Panel WVU Project Team C8 Health Project Results Contact Us Other Links Department Home SoM Home Search: Q Department Health Sciences Center O WVU | C8 Home > C8 Results > Other Clinical Cond. and Diagnoses C8 Health Project Results C8 and Other Clinical Conditions and Diagnoses Print The WVU website is a communication vehicle to depict associations or their public use. These tables and graphs show many comparisons between diag reported and / or validated) and corresponding population serum PFOA (C8) lev appears that there is a clear relationship between serum C8 and a clinical di; meaning of that relationship still requires thought and discussion. Some of the n while real, are weak and not likely to be important. Several are strong, inte potentially important, and none of them can be taken to show an etiologic (cause relationship or its absence without more work. When it comes to causes, scienti these preliminary data with deference to additional work that needs to be done. These data concerning associations are for public use. They will receive collaborative work in peer review format. We hope they prompt public o suggestions of interested scientists. Download Abobe Reader Congenital Malformations, Deformations and Chromosomal Abnormal Defects) Diseases of the Blood and Blood-Forming Organs and Certain Disorders In Immune Mechanism Diseases of the Circulatory System Self-Reported Raynaud's Syndrome (44 KB) Diseases of the Digestive System Diseases of the Genitourinary System Self-Reported Endometriosis (40 KB) Self-Reported Kidney Disease (59 KB) S elf-Reported Uterine Fibroids (40 KB) Diseases of the Musculoskeletal System and Connective Tissue Self-Reported Osteoarthritis (58 KB) Diseases of the Respiratory System http://www.hsc.wvu.edu/som/cmed/c8/results/otherConditionsAndDiagnoses/index.asp 2 /2 /2 0 0 9 WVU :: School of Medicine :: Community Medicine :: C8 Diseases of the Skin and Subcutaneous Tissue Diseases of the Nervous System Self-Reported Parkinson's Disease (35 KB) Endocrine, Nutritional and Metabolic Diseases Self-Reported Thyroid Disease (74 KB) Infectious Diseases Mental and Behavioral Disorders Neoplasms (Cancer) Sch oo l of M edicine | R obert C . Byrd Health S cie n ce s C e n ter | P .O . Box 9 100 | M organtown, W V 26506-9100 W e b m a s te r | Site D esign by W V U W e b S e rv ic e s Plg^ of 2 La st M odified: J a 2009 W est Vir http://www.hsc.wvu.edu/som/cmed/c8/results/otherConditionsAndDiagnoses/index.asp 2 /2 /2 0 0 9 Self-Reported Raynaud's Syndrome and C8/PF0A Adults (>=18YO) Only NQTE: All results reported here are based on information as reported by participants and were not independently verified. The association between self-reported Raynaud's Syndrome and C8/PFOA is unadjusted for any potential confounders or covariates. Caution in interpretation is warranted. Female Quartile Group - C8 1 Count % within Quartile Group - C8 % within Self-Reported Raynaud's Syndrome 2 Count % within Quartile Group - C8 % within Self-Reported Raynaud's Syndrome 3 Count % within Quartile Group - C8 % within Self-Reported Raynaud's Syndrome 4 Count Male Quartile Group - C8 % within Quartile Group - C8 % within Self-Reported Raynaud's Syndrome Total Count % within Quartile Group - C8 % within Self-Reported Raynaud's Syndrome 1 Count % within Quartile Group - C8 % within Self-Reported Raynaud's Syndrome 2 Count % within Quartile Group - C8 % within Self-Reported Raynaud's Syndrome 3 Count % within Quartile Group - C8 % within Self-Reported Raynaud's Syndrome 4 Count % within Quartile Group - C8 % within Self-Reported Raynaud's Syndrome Total Count % within Quartile Group- C8 % within Self-Reported Raynaud's Syndrome Self-Reported Raynaud's Syndrome No/No Response Yes Total 9119 53 9172 99.4% .6% 100.0% 31.1% 27.9% 31.1% 7289 33 7322 99.5% .5% 100.0% 24.9% 17.4% 24.8% 6680 52 6732 99.2% .8% 100.0% 22.8% 27.4% 22.8% 6190 52 6242 99.2% .8% 100.0% 21.1% 27.4% 21.2% 29278 190 29468 99.4% .6% 100.0% 100.0% 100.0% 100.0% 4839 3 4842 99.9% .1% 100.0% 18.1% 10.0% 18.1% 6853 8 6861 99.9% .1% 100.0% 25.7% 26.7% 25.7% 7121 7 7128 99.9% .1% 100.0% 26.7% 23.3% 26.7% 7864 12 7876 99.8% .2% 100.0% 29.5% 40.0% 29.5% 26677 30 26707 99.9% .1% 100.0% 100.0% 100.0% 100.0% 2009 West Virginia University School of Medicine iI p . 15 Participants with Self-Reported Raynaud's Syndrome within C8/PF0A Population Quartile Group Gender H Female I Male Population Quartile Group - C8 C8/PFOAfor Participants Stratified by Self-Reported Raynaud's Syndrome Self-Reported Raynaud's Syndrome I No X Yes 2009 W est Virginia University School of Medicine Self-Reported Endometriosis and C8/PFOA Adult (>=18YO) Women Only NOTE: All results reported here are based on information as reported by participants and were not independently verified. The association between self-reported endometriosis and C8/PFOA is unadjusted for any potential confounders or covariates. Caution in interpretation is warranted. _________ Female Quartile Group -- C8 1 Count % within Quartile Group - C8 % within Self-Reported Endometriosis 2 Count % within Quartile Group - C8 % within Self-Reported Endometriosis 3 Count % within Quartile Group - C8 % within Self-Reported Endometriosis 4 Count % within Quartile Group - C8 % within Self-Reported Endometriosis Totai Count % within Quartile Group- C8 % within Self-Reported Endometriosis Self-Reported Endometriosis No/No Response Yes Total 8113 1059 9172 88.5% 11.5% 100.0% 31.4% 29.3% 31.1% 6415 907 7322 87.6% 12.4% 100.0% 24.8% 25.1% 24.8% 5900 832 6732 87.6% 12.4% 100.0% 22.8% 23.1% 22.8% 5431 811 6242 87.0% 13.0% 100.0% 21.0% 22.5% 21.2% 25859 3609 29468 87.8% 12.2% 100.0% 100.0% 100.0% 100.0% 2009 West Virginia University School of Medicine Number of Participants with Self-Reported Endometriosis 11 p. 17 Number of Participants with Self-Reported Endometriosis within C8/PF0A Population Quartile Group 10,000* Self-Reported Endometriosis No Yes 8 ,000- 1.115 6 ,000- 4,000- 2,000- Population Quartile Group - C8 C8/PFOA for Participants Stratified by Self-Reported Endometriosis C8/PF0A (ng-mL; Mean +/- 95% Cl) 2009 West Virginia University School of Medicine Self-Reported Kidney Disease and C8/PFOA Adults (>=18Y0) Only NOTE: All results reported here are based on information as reported by participants and were not independently verified. The association between self-reported kidney disease and C8/PFOA is unadjusted for any potential confounders or covariates. Caution in interpretation is warranted. Female Quartile Group - C8 Male Quartile Group - C8 1 Count % within Quartile Group - C8 % within Self-Reported Kidney Disease 2 Count % within Quartile Group - C8 % within Setf-Reported Kidney Disease 3 Count % within Quartile Group - C8 % within Self-Reported Kidney Disease 4 Count % wilhin Quartile Group - C8 % within Self-Reported Kidney Disease Total Count % within Quartile Group - C8 % within Self-Reported Kidney Disease 1 Count % wilhin Quartile Group - C8 % within Self-Reported Kidney Disease 2 Count % within Quartile Group - C8 % within Self-Reported Kidney Disease 3 Count % within Quartile Group - C8 % within Self-Reported Kidney Disease 4 Count % within Quartile Group - C8 % within Self-Reported Kidney Disease Total Count % within Quartile Group - C8 % within Self-Reported Kidney Disease Self-Reported Kidney Disease No/No Response Yes Total 8131 1041 9172 88.7% 11.3% 100.0% 30.9% 33.0% 31.1% 6534 788 7322 89.2% 10.8% 100.0% 24.8% 25.0% 24.8% 6079 90.3% 23.1% 653 6732 9.7% 100.0% 20.7% 22.8% 5567 675 6242 89.2% 10.8% 100.0% 21.2% 21.4% 21.2% 26311 3157 29468 89.3% 10.7% 100.0% 100.0% 100.0% 100.0% 4348 494 4842 89.8% 10.2% 100.0% 17.9% 19.9% 18.1% 6240 90.9% 621 6861 9.1% 100.0% 25.8% 25.0% 25.7% 6465 90.7% 26.7% 663 7128 9.3% 100.0% 26.7% 26.7% 7172 91.1% 29.6% 704 7876 8.9% 100.0% 28.4% 29.5% 24225 90.7% 2482 26707 9.3% 100.0% 100.0% 100.0% 100.0% 2009 West Virginia University School of Medicine II p . 19 2009 West Virginia University School o f Medicine C8/PF0A (ng-mL; Mean +/- 95% Cl) % of Participants with Self-Reported Kidney Disease Self-Reported Uterine Fibroids and C8/PFOA Adult (>=18YO) Women Only NOTE: All results reported here are based on information as reported by participants and were not independently verified. The association between self-reported uterine fibroids and C8/PFOA is unadjusted for any potential confounders or covariates. Caution in interpretation is warranted. Self-Reported Uterine Fibriods Female Quartile Group - C8 1 Count % within Quartile Group - C8 % within Self-Reported Uterine Fibriods 2 Count % within Quartile Group - C8 % within Self-Reported Uterine Fibriods 3 Count % within Quartile Group - C8 % within Self-Reported Uterine Fibriods 4 Count % within Quartile Group - C8 % within Self-Reported Uterine Fibriods Total Count % within Quartile Group - C8 % within Self-Reported Uterine Fibriods No/No Response Yes Total 7959 1213 9172 86.8% 31.6% 6257 85.5% 24.8% 5757 85.5% 22.8% 5226 83.7% 20.7% 13.2% 100.0% 28.4% 31.1% 1065 7322 14.5% 100.0% 24.9% 24.8% 975 6732 14.5% 100.0% 22.8% 22.8% 1016 6242 16.3% 100.0% 23.8% 21.2% 25199 4269 29468 85.5% 14.5% 100.0% 100.0% 100.0% 100.0% 2009 West Virginia University School of Medicine ri p. 21 Number of Participants with Self-Reported Uterine Fibroids within C8/PF0A Population Quartile Group Population Quartile Group - C8 C8/PF0A for Participants with Self-Reported Uterine Fibroids 2009 West Virginia University School of Medicine Self-Reported Osteoarthritis and C8/PFOA Adults (>-18Y 0) Only NOTE: All results reported here are based on information as reported by participants and were not independently verified. The association between self-reported osteoarthritis and C8/PFOA is unadjusted for any potential confounders or covariates. Caution in interpretation is warranted. Female Quartile Group - C8 Male Quartile Group - C8 1 Count % within Quartile Group - C8 % within Self-Reported Osteoarthritis 2 Count % within Quartile Group - C8 % within Self-Reported Osteoarthritis 3 Count % within Quartile Group - C8 % within Self-Reported Osteoarthritis 4 Count % within Quartile Group - C8 % within Self-Reported Osteoarthritis Total Count % within Quartile Group -- C8 % within Self-Reported Osteoarthritis 1 Count % within Quartile Group - C8 % within Self-Reported Osteoarthritis 2 Count % within Quartile Group - C8 % within Self-Reported Osteoarthritis 3 Count % within Quartile Group - C8 % within Self-Reported Osteoarthritis 4 Count % within Quartile Group- C8 % within Self-Reported Osteoarthritis Total Count % within Quartile Group - C8 % within Self-Reported Osteoarthritis Self-Reported Osteoarthritis No/No Response Yes Total 8502 670 9172 92.7% 7.3% 100.0% 32.2% 21.8% 31.1% 6625 697 7322 90.5% 9.5% 100.0% 25.1% 22.7% 24.8% 5978 754 6732 88.8% 11.2% 100.0% 22.6% 24.5% 22.8% 5289 953 6242 84.7% 15.3% 100.0% 20.0% 31.0% 21.2% 26394 3074 29468 89.6% 10.4% 100.0% 100.0% 100.0% 100.0% 4618 224 4842 95.4% 4.6% 100.0% 18.2% 16.8% 18.1% 6580 95.9% 281 6861 4.1% 100.0% 25.9% 21.1% 25.7% 6766 362 7128 94.9% 5.1% 100.0% 26.7% 272 % 26.7% 7413 463 7876 94.1% 5.9% 100.0% 29.2% 34.8% 29.5% 25377 1330 26707 95.0% 5.0% 100.0% 100.0% 100.0% 100.0% 2009 West Virginia University School of Medicine Participants with Self-Reported Osteoarthritis within C8/PF0A Population Quartile Group Gender Female Male C8/PFOAfor Participants Stratified by Self-Reported Osteoarthritis Seff-Reported Osteoarthritis I No I Yes Gender 2009 West Virginia University School of Medicine # Self-Reported Parkinson's and C8/PFOA Adults 0 = 1 8YO) Only N O IE : All results reported here are based on information as reported by participants and were not independently verified. The association between self-reported Parkinson's and C8/PFOA is unadjusted for any potential confounders or covariates. Caution in interpretation is warranted. Female Quartile Group -- C8 1 Count % within Quartile Group - C8 % within Self-Reported Parkinson's Disease 2 Count % within Quartile Group- C8 % within Self-Reported Parkinson's Disease 3 Count % within Quartile Group - C8 % within Self-Reported Parkinson's Disease 4 Count % within Quartile Group - C8 % within Self-Reported Parkinson's Disease Total Count % within Quartile Group - C8 Male Quartile Group - C8 1 % within Self-Reported Parkinson's Disease Count % within Quartile Group - C8 % within Self-Reported Parkinson's Disease 2 Count % within Quartile Group - C8 % within Self-Reported Parkinson's Disease 3 Count % within Quartile Group - C8 % within Self-Reported Parkinson's Disease 4 Count % within Quartile Group - C8 % within Self-Reported Parkinson's Disease Total Count % within Quartile Group - C8 % within Self-Reported Parkinson's Disease Self-Reported Parkinson's Disease No/No Response Yes Total 9164 8 9172 99.9% .1% 100.0% 31.1% 17.8% 31.1% 7313 9 7322 99.9% .1% 100.0% 24.9% 20.0% 24.8% 6716 16 6732 99.8% .2% 100.0% 22.8% 35.6% 22.8% 6230 12 6242 99.8% .2% 100.0% 21.2% 26.7% 21.2% 29423 45 29468 99.8% .2% 100.0% 100.0% 100.0% 100.0% 4836 6 4842 99.9% .1% 100.0% 18.1% 11.8% 18.1% 6849 12 6861 99.8% .2% 100.0% 25.7% 23.5% 25.7% 7113 15 7128 99.8% .2% 100.0% 26.7% 29.4% 26.7% 7858 18 7876 99.8% .2% 100.0% 29.5% 35.3% 29.5% 26656 51 26707 99.8% .2% 100.0% 100.0% 100.0% 100.0% 2009 West Virginia University School o f Medicine Participants with Self-Reported Parkinson's Disease within C8/PFOA Population Quartile Group BGender Female Bh/lale C8IPFOA for Participants Stratified by Self-Reported Parkinson's Disease S e lf-R e p o rte d P a rkin so n 's D ise ase I No X Yes 2009 West Virginia University School o f Medicine Self-Reported Thyroid Disease and C8/PFOA Adults 0 = 1 8YO) Only NO TE: All results reported here are based on information as reported by participants and were not independently verified. The association between self-reported thyroid disease and C8/PFO A is unadjusted for any potential confounders or covariates. Caution in interpretation is warranted. F e m a le Q uartile G roup -- C 8 M ale Q uartile G roup -- C 8 1 Count % w ithin Q uartile G ro u p - C 8 % w ithin S e lf-R e p o rte d Thyroid D is e a s e 2 Count % w ithin Q uartile G ro u p - C 8 % w ithin S e lf-R e p o rte d Thyroid D is e a s e 3 Count % w ithin Q uartile G ro u p - C 8 % w ithin S e lf-R e p o rte d Thyroid D is e a s e 4 Count % w ithin Q uartile G ro u p - C 8 % w ithin S e lf-R e p o rte d Thyroid D is e a s e Total Count % w ithin Q uartile G ro u p - C 8 % w ith in S e lf-R e p o rte d Thyroid D is e a s e 1 Count % w ithin Q uartile G ro u p -- C 8 % w ithin S e lf-R e p o rte d Thyroid D is e a s e 2 Count % w ithin Q uartile G roup - C 8 % w ithin S e lf-R e p o rte d Thyroid D is e a s e 3 Count % w ithin Q uartile G roup - C 8 % w ithin S e lf-R e p o rte d Thyroid D is e a s e 4 Count % w ithin Q uartile G roup - C 8 % w ithin S e lf-R e p o rte d Thyroid D is e a s e Total Count % w ithin Q uartile G ro u p - C 8 S e lf-R e p o rte d thyro id D is e a s e n o /n o R e s p o n s e Yes Total 8211 8 9 .5 % 3 1 .7 % 6510 8 8 .9 % 2 5 .1 % 5877 8 7 .3 % 2 2 .7 % 5298 8 4 .9 % 2 0 .5 % 25896 8 7 .9 % 1 00 .0 % 4694 9 6 .9 % 1 8.1 % 6675 9 7.3 % 2 5 .7 % 6942 9 7 .4 % 2 6 .8 % 7614 9 6 .7 % 2 9.4 % 25925 9 7 .1 % 1 00 .0 % 961 1 0 .5 % 2 6.9 % 812 1 1 .1 % 2 2.7 % 855 1 2.7% 2 3.9 % 944 1 5 .1 % 2 6.4% 3572 1 2 .1 % 100 .0 % 148 3 .1% 1 8 .9 % 186 2 .7 % 2 3.8% 186 2 .6 % 2 3.8 % 262 3 .3 % 3 3 .5 % 782 2 .9% 1 0 0 .0 % 9172 1 00 .0 % 3 1 .1 % 7322 1 00 .0 % 2 4 .8 % 6732 1 00 .0 % 2 2 .8 % 6242 1 00 .0 % 2 1 .2 % 29468 1 0 0 .0 % 1 00 .0 % 4842 1 00 .0 % 1 8.1 % 6861 1 0 0 .0 % 2 5 .7 % 7128 1 00 .0 % 2 6 .7 % 7876 1 00 .0 % 2 9 .5 % 26707 1 00 .0 % 1 00 .0 % Fem ale Quartile Group -- C 8 Male Quartile Group -- C 8 1 Count % within Quartile Group - C 8 % within Type Of Self-Reported Thyroid Condition 2 Count % within Quartile Group - C 8 % within Type Of Self-Reported Thyroid Condition 3 Count % within Quartile Group - C 8 % within Type Of S e i-R e p o rte d Thyroid Condition 4 Count % within Quartile Group - C 8 % within Type Of Self-Reported Thyroid Condition Total Count % within Quartile Group - C 8 % within Type Of Self-Reported Thyroid Condition 1 Count % within Quartile Group - C 8 % within Type Of Self-Reported Thyroid Condition 2 Count % within Quartile Group - C 8 % within Type Of Self-Reported Thyroid Condition 3 Count % within Quartile Group - C 8 % within Type Of Self-Reported Thyroid Condition 4 Count % within Quartile Group - C 8 % within Type Of S e f-R eported Thyroid Condition Total Count % within Quartile Group - C 8 % within Type Of Setf-Reported Thyroid Condiion Goiter 135 14.0% 23.9% 136 16.7% 24.0% 144 16.8% 25.4% 151 16.0% 26.7% 566 15.8% 100.0% 11 7.4% 20.4% 17 9.1% 31.5% 13 7.0% 24.1% 13 5.0% 24.1% 54 6.9% 100.0% Type Of Self-Reported Thyroid Condition G rave's d isease Hashim oto's O tter Total 59 6.1% 27.4% 45 5.5% 20.9% 48 5.6% 22.3% 63 6.7% 29.3% 215 6.0% 100.0% 8 5.4% 21.6% 5 2.7% 13.5% 8 4.3% 21.6% 16 6.1% 43.2% 37 4.7% 100.0% 53 714 961 5.5% 743% 100.0% 29.1% 27.4% 26.9% 51 580 812 6.3% 71.4% 100.0% 28.0% 222% 22.7% 30 633 855 3.5% 74.0% 100.0% 16.5% 24.3% 23.9% 48 682 944 5.1% 722% 100.0% 26.4% 251% 26.4% 182 2609 3572 5.1% 730% 100.0% 100.0% 100.0% 100.0% 3 126 148 2.0% 851% 100.0% 12.0% 189% 18.9% 10 154 186 5.4% 828% 100.0% 40.0% 23.1% 23.8% 4 161 186 2.2% 856% 100.0% 16.0% 24.2% 23.8% 8 225 262 3.1% 859% 100.0% 32.0% 338% 33.5% 25 666 782 3.2% 852% 100.0% 100.0% 100.0% 100.0% 2009 West Virginia University School of Medicine % of Participants with Self-Reported Thyroid Disease Participants with Self-Reported Thyriod Disease within C8/PFOA Population Quartile Group 20- Gender H Fem ale M ale 15- 10- 5- 12 34 Population Quartile Group - C8 C8/PFOA for Participants Stratified Self-Reported Thyroid Disease Self-Reported Thyroid Disease I no I Yes C8/PF0A (ng-mL; Mean +/- 95% Cl) 2009 West Virginia University School of Medicine C8/PFOA (ng-mL; Mean +/-95% Cl) C8/PF0A for Participants Stratified by Type of Self-Reported Thyroid Disease Type Of Self Reported Thyroid Condition I Goiter I G rave's disease H a s h im o to 's I Other Gender 2009 West Virginia University School of Medicine School of Medicine :: Community Medicine :: C8 P a f o f 12 Site Map C8 Home what is cs What s New? C8 Health Project Settlement Details Brookmar Project Team Science Panel WVU Project Team C8 Health Project Results ^ Contact Us Other Links Department Home SoM Home Search: O Department () Health Sciences Center O WVU | C8 Home > C8 Results > Other Clinical Lab Values C8 Health Project Results C8 and Other Laboratory Values Print The WVU website is a communication vehicle to depict associations or their public use. These tables and graphs show many comparisons between lal corresponding population serum PFOA (C8) levels. When it appears that ther relationship between serum C8 and a clinical laboratory value, the mear relationship still requires thought and discussion. Some of the relationships, wf weak and not likely to be important. Several are strong, interesting and potential and none of them can be taken to show an etiologic (cause and effect) refatic absence without more work. When it comes to causes, scientists interpret these data with deference to additional work that needs to be done. These data concerning associations are for public use. They will receivi collaborative work in peer review format. We hope they prompt public o suggestions of interested scientists. The results summarized on this page include differences in C8 values based on abnormal clinical laboratory results (normal / abnormal laboratory cutoff values ; referenced on each graph), and for differences on clinical laboratory values b deciles. The files below present the summaries for C8 deciles in a graphical foi results in tabular format, please click here. For a summary of C8 decile cutoffs, here). Download Abobe Reader Other Laboratory Values ABCDEFGHIJKLMNOPQRSIUVWXYZ Alpha-Fetoprotein Tumor Marker (Serum) Description of AFP (39 KB) Serum C8 By AFP for Participants 1-2 Years of Aae (24 KB) Serum C8 By AFP for Participants >= 3 Years of Aae (24 K B ) C8 Population Deciles & Alpha-Fetoprotein Tumor Marker (35 KB) Albumin (Serum) Description of Albumin (37 KB) Serum C8 By Albumin (Serum) Levels In Participants <18 Years Of Aae 12 Serum C8 By Albumin (Serum) Levels In Participants >=18 Years Of Aae (: C8 Population Deciles &Albumin (37 KB) Alkaline Phosphatase (Serum) Description of Alkaline Phosphatase (4 0 K B ) Serum C8 By Alkaline Phosphatase Levels in Participants 1-3 Years of Apt Serum C8 By Alkaline Phosphatase Levels in Participants 4-6 Years of Aor Serum C8 By Alkaline Phosphatase Levels in Participants 7-9 Years of Aar http://www.hsc.wvu.edu/som/cmed/c8/results/otherLaboratoryValues/index.asp 2/2/2009 Girls (Female, <18Y0) G irls (Female, <18Y0) Page 1 Tabular (Numeric) Summary for Clinical Lab Values within Population C8/PF0A Deciles, Stratified by Age & Gender Population D ecile Group - C 8 (P FO A ) 1 Mean M edian Std . Deviation 2 Mean M edian Std. Deviation 3 Mean M edian Std . Deviation 4 Mean M edian Std. Deviation 5 Mean M edian Std. Deviation 6 Mean M edian Std. Deviation 7 Mean M edian Std. Deviation 8 Mean M edian Std. Deviation 9 Mean M edian Std . Deviation 10 Mean M edian Total Std . Deviation M ean M edian Std . Deviation A-G Ratio (Fin al Recoded V alue) 1.63 1.60 0 .2 3 1.65 1.60 0.24 1.62 1.60 0.23 1.65 1.60 0 .2 4 1.66 1.60 0.23 1.64 1.60 0 .2 4 1.66 1.70 0 .2 4 1.67 1.70 0.21 1.68 1.70 0 .2 4 1.69 1.70 0.23 1.65 1.60 0.23 A FP Tumor M arker, Serum ( ng-m L) 3 .3 0 2 .0 0 1 0 .4 9 2 .7 3 2.0 0 7 .9 8 2 .3 3 2 .0 0 2 .8 7 3 .6 0 2.0 0 2 5 .5 3 2 .5 5 2 .0 0 8 .1 5 2 .9 6 2 .0 0 10.39 2 .5 5 2 .0 0 4 .8 7 2 .28 2 .0 0 1 .4 9 2 .1 9 2.0 0 1.26 2 .2 4 2 .0 0 1.21 2 .7 0 2.0 0 10.13 Album in, Serum ( gdL) 4 .5 4 4 .5 0 0 .2 8 4 .5 7 4.6 0 0 .2 7 4 .5 8 4 .6 0 0 .2 7 4.61 4 .6 0 0 .2 8 4 .60 4 .6 0 0 .2 5 4.61 4 .6 0 0 .2 7 4.61 4 .60 0 .2 7 4 .6 4 4.6 0 0 .2 5 4 .6 4 4 .6 0 0 .2 6 4 .6 8 4 .7 0 0 .2 4 4.6 0 4 .6 0 0 .2 7 A lkaline P h o sp h a ta se , Serum ( IU -L) 174.56 139.00 103.88 1 8 0 .6 7 1 6 2 .0 0 9 7 .4 5 1 9 2 .9 8 1 8 8 .5 0 102.21 194.70 2 0 1 .0 0 1 0 3 .3 9 1 9 5 .5 7 1 9 8 .0 0 1 0 2 .9 4 2 0 1 .8 6 195.00 135.74 2 0 1 .6 4 197.50 1 1 4 .6 0 2 1 6 .0 0 2 2 2 .5 0 9 5 .4 5 2 0 7 .1 6 2 1 6 .0 0 98.61 2 0 4 .2 3 2 1 6 .0 0 9 7 .5 6 195.95 1 9 6 .0 0 1 0 6 .8 8 A ntinuclear Antibodies D irect ( A L T (S G P T ) ( IU -L) U-m L) A S T (S G O T ) ( IU -L) 1 6 .8 9 1 5 .0 0 17.46 1 6 .6 3 15.00 9 .8 2 1 7 .5 4 1 5 .0 0 12.86 18.23 15.00 1 6 .7 9 1 6 .7 7 1 5 .0 0 8.9 7 1 6 .4 9 1 5 .0 0 7 .0 4 1 6 .7 8 1 5 .0 0 10.31 1 6 .4 4 1 5 .0 0 6.2 4 16.62 1 5 .0 0 7 .5 3 17.02 1 6 .0 0 6.2 4 1 6 .9 3 1 5 .0 0 1 1 .1 9 2 7 .3 2 23 .0 0 19.81 2 7 .6 3 2 3 .0 0 2 9 .7 3 3 0 .4 4 2 6 .0 0 2 5 .2 9 2 8 .4 9 2 5 .0 0 18.25 29.31 2 5 .0 0 2 0 .9 6 3 0 .2 3 2 6 .0 0 3 6 .0 6 3 0 .8 2 2 6 .0 0 20.31 2 9 .0 2 2 5 .0 0 1 6 .5 3 3 1 .3 8 2 5 .0 0 5 1 .4 4 29 .0 7 2 5 .0 0 18.55 2 9 .3 2 2 5 .0 0 2 7 .7 6 22 .3 5 2 1 .0 0 8 .9 5 22 .8 9 21 .0 0 7 .7 8 23 .6 0 2 2 .0 0 8 .2 7 2 4 .3 6 23 .0 0 10.47 2 4 .2 9 2 2 .0 0 1 5 .6 5 23 .7 7 23 .0 0 6 .7 5 2 4 .4 6 2 4 .0 0 7 .1 9 2 5 .1 8 2 4 .0 0 8 .4 4 25.01 24 .0 0 7 .5 4 2 5 .0 8 2 4 .0 0 7 .1 3 24.01 23 .0 0 9 .1 4 p. 30 2009 West Virginia University School of Medicine Girls (Female, <18Y0) Page 2 Girls (Female, <18Y0) Population Decile Group - C8 (PFOA) Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation 10 Mean Median Std. Deviation Mean Median Std. Deviation Baso (Absolute) ( x10e3-uL) 0,02 0.00 0.04 0.02 0.00 0.04 0.02 0.00 0.04 0.02 0.00 00..0024 0.00 0.04 0.03 0.00 0.04 0.03 0.00 0.05 0.02 0.00 0.04 0.03 0.00 0.05 0.03 0.00 0,04 0.02 0.00 0.04 Bilirubin, Direct ( Basos(% ) mg-dL) 0.23 0.10 0.00 0.09 0.43 0.25 00..1015 0.00 0.43 0.23 0.00 0.09 0.06 0.10 0.09 0.42 0.27 0.00 0.44 0.27 0.00 0.05 0.10 0.09 0.05 0.10 0.09 0.45 0.29 0.00 0.45 0.30 0.00 0.47 0.26 0.00 0.44 0.29 0.05 0.10 0.09 0.05 0.10 0.09 0.05 0.10 0.08 00..1005 0.00 0.09 0.46 0.28 00..1006 0.00 0.09 0.46 0.27 00..1005 0.00 0.09 0.45 0.05 Bilirubin, Total ( mg-dL) 0.35 0.30 0.22 0.40 0.30 0.31 0.35 00..2310 0.36 0.30 0.24 0.36 0.30 0.22 0.35 0.30 0.24 0.36 0.30 0.23 0.36 0.30 0.25 0.38 0.30 0.27 0.37 0.30 0.25 0.36 0.30 0.25 BUN ( mg-dL) 11.77 11.00 132..1052 12.00 3.26 1122..0005 3.14 12.01 12.00 3.12 1121..9004 3.28 1122..0203 3.02 12.44 12.00 3.49 1122..0507 3.36 12.26 12.00 3.00 1122..0303 3.11 12.15 12.00 3.20 BUN-Creatlnine Ratio (Final Calcium, Serum ( Recoded Value) mg-dL) 18.76 10.03 17.00 7.20 19.09 18.00 10.00 0.36 1100..0003 7.34 0.36 19.62 18.00 1100..1004 7.65 19.55 0.36 10.06 18.00 7.44 10.00 0.35 19.73 18.00 8.00 20.28 10.05 10.10 0.35 10.08 19.00 10.10 _7j 20.47 19.00 0.37 1100..1009 8.43 21.34 20.00 0.35 1100..1100 8.36 20.79 19.00 0.34 10.10 10.10 8.14 20.62 19.00 7,84 0.36 10.13 10.10 0.33 19.96 10.07 18.00 7.82 10.10 0.35 Cancer Antigen (CA-125) ( U-mL) 16.59 15.00 8.41 16.84 15.10 8.17 16.45 15.10 8.95 16.47 14.60 9.24 17.08 14.30 19.67 16.91 15.00 8.78 16.57 15.00 7.71 15.59 14.65 6.39 16.23 14.50 8.03 16.95 15.00 10.45 16.58 14.90 10.09 2009 West Virginia University School o f Medicine p. 31 Girls (Female, <18Y0) Page 3 G irls (Female, <18Y0) Population Decile Group -- C8 (PFOA) 1 Median Std. Deviation 2 Mean Median Std. Deviation 3 Mean Median Std. Deviation 4 Mean Median Std. Deviation 5 Mean Median Std. Deviation 6 Mean Median Std. Deviation 7 Mean Median Std. Deviation 8 Mean 9 10 Total Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Chloride, Serum ( Cholesterol, Total ( CEA ( ng-ml) mmol-L) mg-dL) 0.55 0.25 0.51 0.55 0.25 0.47 0.58 0.25 0.50 0.55 0.25 0.41 0.55 0.25 0.45 0.58 0.25 0.49 0.59 0.25 0.55 0.57 0.25 0.47 0.62 0.25 0.65 0.61 0.25 0.56 0.57 0.25 0.51 104.07 104.00 1.89 103.94 104.00 1.95 103.84 104.00 1.95 103.87 104.00 1.85 103.64 104.00 1.93 103.58 103.00 1.98 103.53 104.00 1.91 103.46 103.50 1.90 103.60 103.00 1.94 103.20 103.00 1.97 103.69 104.00 1.94 159.39 156.50 29.53 163.12 160.00 28.67 161.81 159.00 28.13 163.93 161.00 29.77 163.14 160.00 28.97 163.95 161.00 31.61 165.43 161.50 31.08 161.99 160.00 28.54 163.53 160.00 27.61 167.17 166.00 29.34 163.23 160.00 29.42 9.96 8.20 5.85 10.35 8.60 6.34 9.63 8.30 5.47 9.40 8.00 5.39 9.59 8.20 5.88 8.81 7.60 5.25 9.03 7.60 6.11 8.61 7.40 4.86 8.52 7.20 5.16 8.94 7.40 5.19 9.33 7.90 5.63 C-Reactive Protein, Quant ( Creatinine, Serum ( mg-l) mg-dL) 1.69 0.50 4.80 1.46 0.50 2.60 1.65 0.60 3.49 1.63 0.40 5.52 1.58 0.40 7.10 1.90 0.50 6.26 1.56 0.40 4.82 1.50 0.40 3.79 1.46 0.40 4.15 1.41 0.40 4.35 1.59 0.50 4.83 0.67 0.70 0.15 0.67 0.70 0.14 0.65 0.60 0.14 0.65 0.70 0.14 0.64 0.60 0.15 0.65 0.60 0.15 0.65 0.60 0.15 0.63 0.60 0.15 0.63 0.60 0.16 0.64 0.60 0.15 0.65 0.60 0.15 Eos (Absolute) ( Eos ( %) x10e3-uL) 2.33 2.00 2.14 2.42 2.00 2.23 2.53 2.00 3.58 2.46 2.00 2.50 2.43 2.00 2.07 2.46 2.00 2.43 2.44 2.00 2.34 2.33 2.00 1.98 2.57 2.00 2.84 2.49 2.00 2.24 2.44 2.00 2.48 0.18 0.10 0 17 0.18 0.10 0 17 0.20 0.10 0 38 0.19 0.10 0 20 0.18 0.10 0 15 0.19 0.10 0.19 0.19 0.10 0 19 0.18 0 10 0 17 0.20 0 10 0 28 0.19 0 10 0 18 0.19 0 10 0.22 2009 West Virginia University School of Medicine p. 32 Girls (Female, <18Y0) Page 4 Girls (Female, <18Y0) Population Decile Group - C8 (PFOA) 1 Mean Median Std. Deviation 2 Mean Median Std. Deviation 3 Mean Median Std. Deviation 4 Mean Median Std. Deviation 5 Mean Median Std. Deviation 6 Mean Median Std. Deviation 7 Mean Median Std. Deviation 8 Mean Median Std. Deviation 9 Mean Median Std. Deviation 10 Mean Median Std. Deviation Total Mean Median Std. Deviation Estradiol ( pg-mL) Folates (Folic Acid), Serum ( ng- m l) Free Testosterone, Direct ( pg-mL) Free Thyroxine Index (Final Globulin, Total ( g- Glucose, Serum ( H D l Cholesterol ( Recoded Value) GGT ( IU-L) dL) mg-dL) mg-dL) 201.29 32.00 1414.40 114.37 24.00 948.63 62.36 22.50 307.18 98.60 24.00 652.21 65.45 23.00 555.40 119.86 23.00 1161.05 70.11 22.00 696.43 41.79 19.00 141.67 41.47 20.00 56.25 33.63 20.00 35.54 21.03 18.60 9.68 21.89 19.30 9.87 21.24 18.65 9.32 22.21 19.30 9.80 21.55 19.00 9.63 21.01 18.60 9.60 20.45 18.10 9.23 22.04 19.50 9.45 22.52 19.00 10.18 22.28 19.70 9.72 0.55 0.40 0.52 0.56 0.40 0.58 0.53 0.40 0.54 0.52 0.30 0.51 0.53 0.30 0.89 0.55 0.30 0.60 0.52 0.30 0.67 0.52 0.30 0.82 0.43 0.20 0.51 0.46 0.20 0.64 2.25 2.20 0.41 2.26 2.20 0.40 2.27 2.20 0.41 2.28 2.30 0.43 2.29 2.30 0.40 2.33 2.30 0.40 2.35 2.30 0.40 2.31 2.30 0.38 2.31 2.30 0.39 2.29 2.30 0.38 12.07 11.00 7.41 12.12 11.00 4.94 12.83 11.00 6.19 13.20 11.00 11.24 12.16 11.00 5.52 12.33 11.00 5.05 12.22 11.00 5.36 11.65 11.00 4.52 11.68 11.00 3.81 12.09 11.00 4.43 2.83 2.80 0.33 2.82 2.80 0.36 2.88 2.90 0.34 2.84 2.80 0.34 2.81 2.80 0.34 2.86 2.80 0.36 2.83 2.80 0.35 2.82 2.80 0.35 2.81 2.80 0.35 2.82 2.80 0.35 89.53 88.00 19.76 90.33 89.00 18.79 90.84 89.50 18.43 89.24 88.00 11.33 90.77 89.00 18.57 90.30 89.00 13.47 90.05 88.00 12.24 89.40 88.00 13.96 89.51 89.00 14.26 89.95 89.00 13.12 50.15 49.00 10.91 51.09 50.00 11.76 49.78 49.00 11.30 51.35 51.00 11.83 50.93 50.00 10.81 50.45 49.00 11.62 51.76 50.00 10.91 51.42 51.00 11.12 50.04 49.00 10.36 50.92 50.00 11.14 89.04 21.58 0.52 2.29 12.24 2.83 90.02 50.77 23.00 784.26 19.00 9.66 0.30 0.63 2.30 11.00 0.40 6.19 2.80 0.35 89.00 15.87 50.00 11.21 2009 West Virginia University School of Medicine p. 33 Girls (Female, <18Y0) Page 5 Girls (Female, <18Y0) Population Decile Group - C8 (PFOA) 1 Mean Median Std. Deviation 2 Mean Median Std. Deviation 3 Mean Median Std. Deviation 4 Mean Median Std. Deviation 5 Mean Median Std. Deviation 6 Mean Median Std. Deviation 7 Mean Median Std. Deviation 8 Mean Median Std. Deviation 9 Mean Median Std. Deviation 10 Mean Median Total Std. Deviation Mean Median Std. Deviation Hematocrit ( %) 39.44 39.40 2.56 39.51 39.50 2.51 39.51 39.40 2.54 39.61 39.60 2.61 39.79 39.70 2.56 39.40 39.30 2.57 39.52 39.50 2.76 39.34 39.30 2.69 39.47 39.40 2.48 39.71 39.70 2.42 39.52 39.50 2.57 Immunoglobulin A, Hemoglobin ( g-dL) Qn, Serum ( mg-dL) 13.39 150.51 13.40 0.86 13.45 13.40 0.82 13.45 142.00 70.98 144.17 134.00 69.23 152.67 13.40 0.85 13.48 13.50 0.86 13.51 13.50 0.85 13.37 13.40 0.84 13.43 13.40 0.90 13.36 13.40 0.90 13.43 13.40 0.82 13.51 13.50 0.79 144.00 70.00 141.35 131.00 70.57 139.02 132.00 71.62 139.76 130.00 65.01 137.60 128.00 67.10 130.24 118.00 68.65 132.21 125.00 67.24 132.46 124.00 65.59 13.44 13.40 140.58 131.00 0.85 68.99 Immunoglobulin Immunoglobulin G, Immunoglobulin M, Insulin, Fasting ( E, Total ( lU-mL) Qn, Serum ( mg-dL) Qn, Serum ( mg-dL) ulU-mL) 92.80 17.00 411.57 91.38 18.00 1047.55 1035.00 227.28 1035.65 1012.00 126.98 118.50 55.67 130.59 121.00 22.20 13.70 29.86 19.89 12.30 262.68 130.18 20.00 606.50 93.52 16.00 360.84 87.74 18.00 234.13 97.65 17.00 445.35 109.71 238.17 1064.68 1055.00 227.86 1038.90 1023.50 237.94 1007.31 1005.00 215.10 1026.48 1007.00 227.99 1006.03 58.20 127.56 119.50 56.70 128.03 115.50 62.64 134.20 126.00 66.81 134.95 124.50 61.29 129.68 24.32 20.76 12.40 31.56 20.65 10.90 33.02 19.29 10.90 29.09 19.08 12.00 27.90 19.23 19.00 454.36 74.17 16.00 184.85 122.69 18.00 617.77 91.23 16.00 231.98 99.32 17.00 410.24 999.00 229.69 996.13 976.00 214.67 998.59 992.00 240.98 1001.52 987.00 237.23 1023.94 1010.00 230.81 124.00 58.26 124.73 116.00 55.96 127.57 116.00 59.48 126.33 116.00 58.97 129.22 120.00 59.43 11.40 25.26 18.15 11.85 20.41 17.16 11.60 19.92 19.96 12.30 28.07 19.70 12.00 27.33 2009 West Virginia University School of Medicine p. 34 Girls (Female, <18Y0) Page 6 Girls (Female, <18Y0) Population Decile Group -- C8 (PFOA) 2 3 4 5 6 1 3 9 10 Total Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Insulin-Like Growth Factor 1( ng-ml) 338.49 337.00 145.68 322.62 310.00 139.22 301.68 279.00 141.31 317.05 308.00 141.43 304.51 285.00 146.99 291.09 281.00 134.66 302.31 295.00 142.89 282.54 264.00 140.40 296.63 269.00 148.86 281.67 266.00 135.61 305.17 292.00 142.64 Iron, Serum ( ugdL) 84.00 79.00 36.84 84.76 82.00 35.21 81.29 79.50 31.96 84.52 81.00 34.74 84.88 80.00 37.80 78.56 76.00 34.08 82.49 77.50 35.11 80.88 77.00 33.75 84.41 81.00 36.53 81.22 81.00 33.80 82.72 79.00 35.06 LDL Cholesterol ( LDH ( IU-L) 194.11 185.00 49.16 198.17 190.00 48.91 202.36 197.00 50.86 201.40 198.00 48.50 204.33 197.50 58.40 204.63 199.00 49.30 205.83 202.50 46.43 211.30 212.00 49.08 206.58 205.00 46.74 207.77 210.00 47.24 203.25 86.13 84.00 25.30 89.01 87.00 24.26 89.09 87.00 24.01 90.21 88.00 25.25 89.38 87,00 25.92 89.45 87.00 25.32 90.91 89.00 26.95 86.92 85.00 25.99 90.18 87.00 25.04 91.26 90.00 24.88 89.19 199.00 49.75 87.00 25.31 Lymphs (Absolute) ( Lymphs ( %) x10e3-uL) 34.66 34.00 9.56 34.45 34.00 8.60 33.98 34.00 8.95 34.65 34.00 9.11 35.17 34.00 9.19 34.62 34.00 9.30 35.27 2.47 2.40 0.77 2.47 2.40 0.74 2.48 2.40 0.77 2.51 2.40 0.76 2.58 2.50 0.81 2.59 2.50 0.77 2.60 35.00 8.76 35.52 35.00 9.11 35.42 35.00 9.49 35.53 35.00 9.40 2.50 0.76 2.63 2.50 0.82 2.58 2.50 0.83 2.66 2.60 0.87 34.88 2.55 34.00 9.14 2.40 0.79 Magnesium, MCH ( pg) MCHC ( g-dL) 2.01 2.00 0.14 2.03 2.00 0.14 2.04 2.00 0.15 2.04 2.00 0.14 2.04 2.00 0.14 2.04 2.00 0.14 2.05 2.00 0.14 2.08 2.10 0.15 2.07 2.10 0.15 2.08 2.10 0.14 2.05 2.00 0.14 29.61 29.70 1.65 29.69 29.70 1.51 29.53 29.60 1.58 29.57 29.60 1.53 29.42 29.50 1.68 29.34 29.40 1.58 29.48 29.50 1.54 29.32 29.40 1.58 29.40 29.40 1.48 29.41 29.40 1.46 29.49 29.50 33.96 34.00 0.62 34.06 34.10 0 60 34.04 34.10 0.64 34.04 34.10 0.58 33.98 34.00 0.67 33.95 34.00 0.63 33.99 34.00 0.60 33.96 34.00 0.62 34.02 34.00 0 58 34.02 34.00 0 58 34.00 34.00 0.61 2009 West Virginia University School of Medicine p. 35 Girls (Female, <18Y0) Page 7 Girls (Female, <18Y0) Population Decile Group - C8 (PFOA) 1 2 3 4 5 6 7 8 9 10 Total Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation MCV ( fL) 87.22 88.00 4.44 87.22 87,00 4.09 86.77 87.00 4.19 86.93 87.00 4.21 86.61 87.00 4.42 86.46 86.00 4.32 86.78 87.00 4.31 86.36 86.00 4.36 86.47 86.00 4.09 86.47 86.50 4.13 86.75 87.00 4.27 Monocytes(Absolute; Monocytes ( %) (x10e3-uL) 6.50 6,00 2.01 6.52 6.00 1.99 6.43 6.00 1.96 6.41 6.00 2.00 6.39 0.47 0.40 0.16 0.47 0.50 0.18 0.48 0.50 0.18 0.47 0.40 0.16 0.47 6.00 2.09 6.48 6.00 1.77 6.46 0.50 0.18 0.49 0.50 0.16 0.48 6.00 1.97 6.50 6.00 1.93 6.34 6.00 1.84 6.26 6,00 1.95 6.43 0.50 0.16 0.48 0.50 0.17 0.47 0.50 0.16 0.47 0.50 0.17 0.47 6.00 0.50 1.95 0.17 Neutrophils ( %) 56.29 57.00 10.29 56.36 57.00 9.59 56.83 57.00 9.89 56.21 56.00 9.99 55.74 56.00 10.00 56.15 57.00 10.09 55.53 56.00 9.66 55.39 55.00 9.93 55.38 56.00 10.28 55.45 56.00 10.31 55.97 56.00 9.99 Neutrophils (Absolute) ( x10e3- uL) 4.22 3.95 1.62 4.24 3.90 1.68 4.37 4.20 1.73 4.28 4.00 1.64 4.28 4.00 1.72 4.45 4.20 1.85 4.26 4.00 1.63 4.26 4.00 1.66 4.21 3.90 1.64 4.35 4.00 1.82 4.29 4.00 1.70 Phosphorus, Platelets ( x10e3- Potassium, Serum Serum ( mg-dL) uL) ( mmol-L) 4.48 316.99 4.50 311.00 0.70 75.46 4.55 314.45 4.50 309.00 0.74 69.87 4.54 323.85 4.50 316.50 0.71 74.48 4.60 317.09 4.60 310.50 0.69 70.09 4.62 316.82 4.60 311.00 0.80 74.00 4.58 321.65 4.60 315.00 0.69 72.34 4.62 317.47 4.60 312.00 0.73 69.76 4.73 321.27 4.70 313.00 0.80 72.29 4.69 314.32 4.70 310.00 0.77 70.30 4.76 322.56 4.80 319.00 0.73 73.97 4.61 318.54 4.60 312.00 0.74 ___________ 72.28 4.14 4 10 0 29 4.09 4 10 0 28 4.10 4 10 0 26 4.12 4 10 0 27 4.09 4 10 0 30 4.11 4.10 0 29 4.10 4.10 0 31 4.10 4 10 0 30 4.12 4 10 0 31 4.12 4 10 0 27 4.11 4 10 0.29 2009 West Virginia University School of Medicine p. 36 Boys (Malo, <18Y0) Page 8 Boys (Male, <18Y0) Tabular (Numeric) Summary for Clinical Lab Values within Population C8/PF0A Deciles, Stratified by Age & Gender Population Decile Group -- C 8 (PFO A ) 1 Mean Median Std. Deviation 2 Mean Median Std. Deviation 3 Mean Median Std. Deviation 4 Mean Median Std. Deviation 5 Mean Median Std. Deviation 6 Mean Median Std. Deviation 7 Mean Median Std. Deviation 8 Mean Median Std. Deviation 9 Mean Median Std. Deviation 10 Mean Median Std. Deviation Total Mean Median Std. Deviation A-G Ratio (Final Recoded Value) 1.89 1.70 A FP Tumor Marker. Serum ( ng-mL) Albumin, Serum ( gdL) 2.06 2.00 4.59 4.60 Alkaline Phosphatase, Serum ( IU-L) Antinuclear Antibodies Direct ( UA LT (S G P T ) ( IU-L) m l) A S T (SG O T) ( IU-L) 247.07 247.00 20.27 17.00 25.17 22.00 26.76 26.00 Baso (Absolute) ( x10e3-uL) 0.02 0.00 Basos(% ) 0.22 0.00 Bilirubin, Direct ( mg-dL) 0,11 0.10 3.62 0.96 0.29 84.46 13.05 12.76 8.38 0.04 0.41 0.06 1.71 1.70 2.06 2.00 4.62 4.60 245.82 241.00 20.79 18.00 27.98 23.00 26.87 25.00 0.02 0.00 0.27 0.00 0.12 0.10 0.23 1.12 0.26 120.76 17.43 40.84 12.86 0.04 0.44 0.06 1.68 1.70 2.08 2.00 4.62 4.60 241.96 233.00 19.66 17.00 28.52 23.00 26.25 25.00 0.02 0.00 0.27 0.00 0.11 0.10 0.23 1.29 0.25 121.39 10.50 25.44 8.64 0.04 0.44 0.06 1.72 1.70 2.14 2.00 4.66 4.70 235.14 227.00 20.70 17.00 26.39 23.00 27.57 27.00 0.02 0.00 0.26 0.00 0.11 0.09 0.23 1.25 0.25 104.31 13.41 16.48 11.97 0.04 0.44 0.06 1.71 1.70 2.09 2.00 4.63 4.60 243.59 239.00 19.81 17.00 29.14 25.00 26.37 25.00 0.03 0.00 0.30 0.00 0.11 0.09 0.23 1.23 0.25 99.32 11.21 29.75 7.04 0.04 0.46 0.06 1.70 1.70 2.06 2.00 4.63 4.60 239.76 237.00 20.13 17.00 31.24 24.00 26.31 25.00 0.03 0.00 0.36 0.00 0.11 0.09 0.24 1.00 0.25 93.03 11.52 58.96 7.32 0.05 0.49 0.06 1.71 1.70 2.05 2.00 4.67 4.70 250.03 244.00 19.59 17.00 29.84 25.00 26.89 26.00 0.03 0.00 0.34 0.00 0.11 0.09 0.22 0.91 0.24 142.46 10.40 28.25 7.27 0.05 0.49 0.06 1.72 1.70 2.14 2.00 4.66 4.70 246.07 242.50 19.47 17.00 28.91 26.00 26.95 26.00 0.03 0.00 0.34 0.00 0.11 0.09 0.23 2.22 0.25 93.68 10.42 15.23 7.73 0.05 0.48 0.06 1.71 1.70 0.23 2.11 2.00 0.91 4.66 4.70 0.24 246.16 238.50 94.08 19.44 17.00 10.47 27.50 24.00 21.65 26.89 26.00 6.78 0.03 0.00 0.05 0.36 0.00 0.49 0.11 0.09 0.06 1.72 1.70 2.14 2.00 4.68 4.70 244.01 241.00 20.01 17.00 28.00 24.00 27.10 26.00 0.03 0.00 0.32 0.00 0.10 0.09 0.23 1.21 0.25 90.63 11.22 15.70 7.24 0.05 0.48 0.06 1.72 1.70 2.09 2.00 4.64 4.60 244.04 239.00 19.98 17.00 28.45 24.00 26.79 26.00 0.03 0.00 0.31 0.00 0.11 0.09 0.95 1.29 0.25 106.91 12.16 30.71 8.78 0.05 0.47 0.06 2009 W est Virginia University School of Medicine p. 37 Boys (Mele, <18Y0) Page 9 Boys (Male, <18Y0) Population Decile Group - C8 (PFO A ) 1 Mean Median Std. Deviation i Mean Median Std. Deviation ^ Mean Median Std. Deviation 4 Mean Median Std. Deviation 5 Mean Median Std. Deviation 6 Mean Median Std. Deviation 7 Mean Median Std. Deviation 8 Mean Median Std. Deviation 9 Mean Median Std. Deviation 10 Total Mean Median Std. Deviation Mean Median Std. Deviation Bilirubin, Total ( mg-dL) 0.4C 0.3C 0.26 0,43 0.30 0.32 0.41 0.30 0.29 0.41 0.30 0.31 0.41 0.30 0.31 0.39 0.30 0.28 0.40 0.30 0.30 0.41 0.30 0.32 0.39 0.30 0.26 0.39 0.30 0.31 0.41 0.30 0.30 BUN ( mg-dL) 13.01 13.00 3.26 13.12 13.00 3.45 13.39 13.00 4.46 13.36 13.00 3.41 13.35 13.00 3.46 13.40 13.00 3.33 13.56 13.00 3.42 13.39 13.00 3.48 13.32 13.00 3.30 13.39 13.00 3.47 13.34 13.00 3.53 Ratio (Final Recoded Value) 20.26 19.00 8.46 19.63 18.00 7.75 20.04 19.00 7.46 20.72 19.00 8.32 20.73 19.50 8.33 20.60 19.00 8.05 21.16 20.00 8.83 21.10 20.00 8.63 21.09 20.00 8.47 21.05 19.00 8.79 20.65 19.00 8.33 Calcium, Serum ( mg-dL) 10.05 10.10 0.34 10.05 10.00 0.34 10.06 10.10 0.33 10.08 10.10 0.33 10.07 10.10 0.34 10.07 10.10 0.33 10.08 10.10 0.33 10.08 10.10 0.34 10.10 10.10 0.32 10.11 10.10 0.34 10.08 10.10 0.33 C an cer Antigen (CA-125) ( U-mL) C E A ( ng-mL) 13.62 12.75 0.67 0.50 6.25 0.54 13.75 12.35 0.70 0.50 6.16 0.59 13.57 12.30 0.71 0.50 6.63 0.62 13.89 12.70 0.71 0.50 6.19 0.63 13.86 12.50 0.74 0.50 7.04 0.67 14.46 13.10 0.73 0.60 7.35 0.68 14.47 13.40 0.70 0.50 6.79 0.59 13.99 13.10 0.70 0.50 6.02 0.60 13.81 12.60 0.70 0.50 6.23 0.66 14.24 13.20 0.67 0.50 6.24 0.59 13.99 12.80 0.70 0.50 6.51 0.62 Chleride, Serum ( Cholesterol, Total ( 103.38 103.00 2.01 103.34 103.00 2.00 103.02 103.00 1.94 103.14 103.00 1.96 102.99 103.00 2.02 103.08 103.00 1.93 102.96 103.00 1.91 102.91 103.00 1.84 102.90 103.00 1.83 102.84 103.00 2.03 103.04 103.00 1.95 153.53 152.00 30.42 156.25 154.00 28.34 157.12 154.00 29.09 157.85 157.00 28.74 156.78 154.00 27.86 159.02 156.00 29.69 160.08 158.00 28.16 160.24 157.00 28,27 159.60 156.50 29.79 160.27 159.00 30.06 158.30 156.00 29.04 02009 We* Virginia University School of Medicine C-Reactive Protein, Quant ( 9.75 9.00 4.33 10.43 9.45 4.78 9.76 8.90 4.72 9.86 9.20 4.92 9.12 8.40 4.47 9.06 8.40 4.35 9.03 8.00 4.66 9.13 8.20 4.71 9.18 8.30 4.63 8.82 8.00 4.55 9.40 8.50 4.65 1.62 0.40 4.18 1.38 0.50 3.88 2.06 0.50 8.51 1.20 0.40 2.98 1.50 0.40 4.25 1.43 0.40 3.54 1.15 0.40 4.18 1.32 0.40 6.64 1.31 0.40 3.55 1.52 0.40 4.85 1.44 0.40 4.97 p. 38 Soys (Male, <18YO) Paga10 Boys (Male, <18YO) Population Decile Group - C8 (P FO A ) Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Creatinine, Serum ( mg-dL) Eos ( %) 0.70 0.70 2.93 2.00 0.20 2.46 0.72 0.70 2.77 2.00 0.19 2.34 0.72 0.70 2.81 2.00 0.26 2.40 0.71 0.70 2.80 2.00 0.21 2.71 0.70 0.70 2.78 2.00 0.20 2.44 0.71 2.91 0.70 2.00 0.20 2.75 0.70 0.70 2.82 2.00 0.20 2.36 0.69 0.70 2.83 2.00 0.19 2.42 0.69 0.60 2.79 2.00 0.20 2.35 0.69 0.70 2.75 2.00 0.19 2.38 0.70 0.70 2.82 2.00 0.21 2.46 Eos (Absolute) ( x10e3-uL) 0.20 0.20 0.17 0.19 0.10 0.17 0.20 0.20 0.18 0.21 0.10 0.21 0.20 0.20 0.18 0.21 0.20 0.22 0.20 0.20 0.18 0.21 0.20 0.19 0.21 0.10 0.19 0.21 0.10 0.20 0.20 0.10 0.19 Folates (Folic Acid), Estradiol ( pg-mL) Serum ( ng-mL) 16.86 16.00 22.11 19,25 9.19 9.65 16.26 16.00 21.67 19.20 9.24 9.52 15.31 15.00 21.91 19.00 8.84 9.81 15.08 14.00 21.62 18.85 9.01 9.44 15.37 14.00 21.33 18.45: 8.71 9.48 16.10 15.00 20.96 18.60 8.70 9.13 15.12 14.00 21.36 18.50 8.81 9.17 14.46 13.00 21.52 19.15 8.57 9.38 15.38 15.00 22.58 19.10 8.08 9.58 14.99 14.00 22.74 19.60 8.52 9.65 15.45 15.00 21.76 19.00 8.78 9.48 Free Testosterone, Direct ( pg-m l) 4.63 3.00 4.88 4.78 1.95 5.34 4.53 1.10 5.45 4.57 1.00 5.70 4.47 0.90 5.63 4.67 1.30 5.80 4.19 0.60 5.66 4.01 0.60 5.30 3.99 0.60 5.48 3.78 0.40 5.16 4.35 0.85 5.46 Free Thyroxine Index (Final Recoded Value) G G T ( IU-L) 2.18 2.20 14.82 13.00 0.39 7.80 2.17 2.20 15.72 13.00 0.39 14.31 2.19 2.20 15.34 13.00 0.41 9.61 2.21 2.20 15.50 13.00 0.41 8.69 2.20 2.20 15.31 13.00 0.39 8.93 2.21 2.20 14.92 13.00 0.38 6.15 2.24 2.20 14.70 13.00 0.39 8.04 2.27 2.30 14.62 13.00 0.39 6.93 2.26 2.30 14.45 13.00 0.45 7.01 2.22 2.20 14.69 13.00 0.39 8.08 2.22 2.20 15.01 13.00 0.40 8.92 Globulin, Total ( gdL) 2.73 2.70 0.36 2.74 2.70 0.33 2.79 2.80 0.33 2.74 2.70 0.32 2.75 2.70 0.33 2.77 2.80 0.34 2.76 2.70 0.33 2.76 2.70 0.33 2.76 2.70 0.33 2.76 2.70 0.33 2.76 2.70 0.33 Glucose, Serum ( mg-dL) 93.34 92.00 19.73 93.30 92.00 14.36 92.91 91.00 15,84 92.72 92.00 13.57 92.37 91.00 12.95 92.61 91.00 13.13 93.12 91.00 17.95 92.69 92.00 12.56 93.44 91.00 16.12 92.57 91.00 20.94 92.89 92.00 15.85 92009 West Virginia University School of Madieine p. 39 Boys (Mals, <18Y0) Page 11 Boys (Male, <18Y0) Population Decile Group - C 8 (P FO A ) 4 4 B ' 8 a 10 Total Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation HDL Cholesterol ( mg-dL) 46.64 45.00 11.21 47.95 47.00 11.72 47.99 46.00 11.82 47.81 47.00 10.93 47.83 47.00 10.91 47.80 47.00 11.11 48.46 47.00 11.81 47.82 47.00 11.00 48.63 48.00 11.15 48.03 47.00 10.80 47.94 47.00 11.27 Hematocrit ( %) 41.31 40.9C 4.03 41.59 41.30 3.66 41.56 41.20 3.81 41.41 41.10 3.89 41.36 40.80 4.03 41.59 41.10 3.90 41.27 40.90 3.77 41.36 40.90 3.76 41.38 41.00 3.68 41.43 41.00 3.69 41.43 41.00 3.81 Immunoglobulin A. Hemoglobin ( g- Qn, Serum ( mg- Immunoglobulin E , dL) dL) 14.08 14.00 146.85 135.00 95.91 22.00 1.33 76.95 216.29 14.19 14.10 145.77 136.00 110.45 29.00 1.20 70.20 252.44 14.18 14.10 152.46 140.00 121.66 28.00 1.26 71.94 270.40 14.12 14.00 139.04 130.00 105.02 24.00 1.26 68.05 366.52 14.09 13.90 138.74 126.00 154.93 29.50 1.33 69.51 560.71 14.16 14.00 140.44 129.00 140.43 28.00 1.29 71.72 304.29 14.06 13.90 136.24 127.00 148.13 26.00 1.25 66.10 589.17 14.08 13.90 133.56 125.50 121.16 28.00 1.24 61.91 249.54 14.08 13.90 135.67 127.00 125.82 26.00 1.22 68.70 281.14 14.13 14.00 137.82 131.00 125.05 27.00 1.21 66.13 261.12 14.12 14.00 140.40 131.00 125.92 27.00 1.25 68.99 359.11 Qn, Serum ( mgdL) 984.05 987.00 225.97 1009.00 992.00 224.70 1023.22 1024.00 211.05 978.64 966.00 214.49 970.77 956.50 221.08 988.82 977.50 225.14 974.63 955.00 225.79 973.48 965.00 223.89 974.31 949.00 223.71 981.68 974.00 216.57 986.23 975.00 221.78 Immunoglobulin M, Qn, Serum ( mg-dL) 92.30 83.00 47.65 92.88 88.00 42.96 96.65 89.00 44.44 94.63 86.00 48.33 93.26 85.00 45.10 95.48 86.00 46.37 96.28 88.00 47.26 96.76 89.00 46.35 95.33 88.00 44.93 98.84 89.00 48.07 95.41 87.00 46.11 Insulin, Fasting ( ulU-m l) Insulin-Like Growth Factor I ( 20.00 12.40 281.52 274.00 31.24 21.44 13.00 134.19 284.54 263.00 34.52 138.34 19.21 11.00 264.74 243.00 26.40 129.15 19.07 11.40 258.63 244.00 36.53 138.16 17.90 10.75 265.53 257.00 24.25 133.83 20.09 11.70 265.91 254.00 36.30 137.62 17.83 10.40 252.00 230.00 24.25 133.92 18.51 12.20 249.59 231.50 23.28 125.77 18.69 10.50 251.26 223.50 31.20 132.97 17.06 11.15 247.58 231.50 20.91 125.17 18.97 11.40 261.49 244.00 29.23 133.29 02009 W est Virginia University School of Medicine p. 40 Boys (Male, <18YO) Page 12 Boys (Male, <18YO) Population Decile Group - C8 (PFO A ) Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviaticn Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation 10 Total Mean Median Std. Deviation Mean Median Std. Deviation Iron, Serum ( ugdL) ID H ( IU-L) 85.98 82.00 214.38 214.00 37.97 48.65 90.04 87.00 213.08 212.00 35.19 47.88 86.92 84.00 211.85 214.00 33.31 47.20 87.16 82.00 217.14 219.00 33.44 48.08 86.30 82.50 212.68 212.00 37.18 45.26 84.90 82.00 214.62 214.00 33.79 44.52 84.36 81.00 217.68 218.50 33.25 46.11 85.61 82.00 216.97 216.50 32.68 42.86 86.54 83.00 219.78 219.00 34.76 43.12 84.39 81.00 219.77 220.00 34.31 43.86 86.21 83.00 215.86 216.00 34.46 45.69 LD L Cholesterol ( Calculated) 81.95 79.00 26.18 84.18 83.00 24.65 84.41 82.50 24.43 86.19 85.00 25.78 84.95 84.00 23.97 86.55 84.00 25.69 86.13 85.00 23.82 86.59 85.00 23.57 86.47 83.00 26.33 86.27 85.00 25.04 85.50 84.00 24.89 Lymphs (Absolute) ( Lymphs ( %) x10e3-uL) 36.01 36.00 2.48 2.30 9.10 0.88 35.08 35.00 2.36 2.30 8.44 0.69 34.67 34.00 2.44 2.30 8.43 0.72 35.25 36.00 2.50 2.40 8.90 0.75 35.31 35.00 2.47 2.30 8.80 0.72 35.36 35.00 2.50 2.40 8.77 0.74 36.06 36.00 2.55 2.50 8.37 0.76 35.75 35.00 2.52 2.40 8.48 0.77 35.35 35.00 2.50 2.40 9.04 0.75 36.21 35.00 2.58 2.50 9.14 0.76 35.50 35.00 2.49 2.40 8.73 0.75 M a g n e siu m , Serum ( mg-dL) 2.05 2.00 MCH ( pg) 29.24 29.20 M CHC ( g-dL) 34.09 34.10 M CV ( fU) 85.83 86.00 Monocytes(Absolute) Monocytes ( %) ( x10e3-uL) 7.16 7.00 0.49 0.50 0.14 1.58 0.62 4.39 2.17 0.17 2.05 2.10 29.41 29.50 34.14 34.10 86.16 86.00 7.28 7.00 0.49 0.50 0.14 1.45 0.57 4.11 2.12 0.17 2.06 2.10 29.40 29.40 34.14 34.20 86.14 86.00 7.13 7.00 0.50 0.50 0.14 1.46 0.60 4.05 2.14 0.18 2.06 2.10 29.36 29.40 34.13 34.10 86.07 86.00 6.92 7.00 0.49 0.50 0.14 1.44 0.63 4.03 2.02 0.16 2.07 2.10 29.19 29.30 34.08 34.10 85.71 86.00 7.14 7.00 0.50 0.50 0.13 1.57 0.59 4.25 1.91 0.16 2.08 2.10 29.29 29.30 34.05 34.00 86.08 86.00 7.32 7.00 0.52 0.50 0.13 1.36 0.60 3.77 2.22 0.18 2.09 2.10 29.23 29.20 34.07 34.00 85.86 86.00 7.16 7.00 0.51 0.50 0.14 1.45 0.59 4.05 1.98 0.18 2.08 2.10 29.19 29.10 34.06 34.10 85.74 86.00 7.12 7.00 0.50 0.50 0.13 1.49 0.57 4.20 2.06 0.17 2.09 2.10 29.11 29.20 34.05 34.00 85.53 86.00 7.19 7.00 0.51 0.50 0.14 1.52 0.59 4.15 1.99 0.17 2.10 2.10 29.21 29.20 34.12 34.10 85.61 85.00 7.10 7.00 0.51 0.50 0.13: 1.43 0.58 3.83 2.09 0.18 2.08 2.10 29.26 29.30 34.09 34.10 85.88 86.00 7.16 7.00 0.50 0.50 0.14 1.47 0.59 4.07 2.07 0.17 2009 West Virginia University School of Medicine I V 'd Boys (Maie, <18Y0) Page 13 Boys (Male, <18YO) Population Decile Group - C8 (PFO A ) * 3 4 5 0 ' 0 9 oiai Median Std. Deviation Mean Median Std. Deviation Mean Median Std, Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Neutrophils ( %) 53.68 54.0C (Absolute) ( x10e3u l) 3.83 3.50 9.88 1.59 54.60 55.00 3.84 3.60 9.27 1.49 55.12 56.00 4.10 3.70 9.50 1.78 54.77 55.00 4.06 3.80 9.98 1.57 54.47 55.00 4.01 3.70 9.91 1.62 54.05 54.00 4.04 3.70 9.95 1.74 53.62 54.00 3.93 3.70 9.41 1.48 53.95 54.00 3.92 3.70 9.33 1.42 54.32 54.00 3.99 3.70 9.85 1.49 53.63 54.00 4.04 3.70 10.25 1.76 54.22 54.00 3.98 3.70 9.72 1.60 Phosphorus, 4.76 4.80 Platelets ( x10e3- Potassium, Serum UL) 316.63 305.00 4.16 4.10 0.72 78.15 0.27 4.67 4.70 306.76 302.00 4.14 4.10 0.73 74.47 0.29 4.77 4.80 308.78 303.00 4.13 4.10 0.69 67.96 0.30 4.74 4.70 312.72 307.00 4.12 4.10 0.69 73.59 0.26 4.83 4.90 303.95 293.00 4.14 4.10 0.70 71.45 0.29 4.75 4.80 311.98 302.50 4.15 4.10 0.70 81.29 0.29 4.79 4.80 305.98 300.00 4.14 4.10 0.69 68.19 0.31 4.73 4.80 310.18 302.00 4.15 4.10 0.67 73.17 0.30 4.84 4.90 0.72 318.08 310.00 72.23 4.16 4.10 0.29 4.86 4.90 314.03 305.00 4.17 4.20 0.71 72.56 0.32 4.77 4.80 310.61 303.00 4.15 4.10 0.70 73.37 0.29 2009 W est Virginia University School of Medicine 7.22 6.50 Antigen, Serum ( Protein, Total, ng-mL) RDW ( %) 0.23 0.05 7.32 7.30 13.74 13.50 3.78 0.27 0.41 0.91 7.06 6.30 0.24 0.05 7.36 7.40 13.65 13.60 3.71 0.41 0.41 0.69 7.33 6.50 0.21 0.05 7.41 7.40 13.57 13.50 3.85 0.29 0.38 0.75 7.43 6.40 0.19 0.05 7.40 7.40 13.58 13.40 4.42 0.22 0.40 0.78 7.44 6.50 0.19 0.05 7.38 7.40 13.57 13.50 4.46 0.25 0.40 0.76 7.36 6.40 0.20 0.05 7.40 7.40 13.56 13.50 4.27 0.24 0.41 0.70 7.41 6.40 0.19 0.05 7.43 7.40 13.54 13.50 4.19 0.25 0.41 0.73 7.42 6.60 0.18 0.05 7.42 7.40 13.48 13.40 3.59 0.23 0.39 0.68 7.39 6.40 0.18 0.05 7.42 7.40 13.57 13.50 4.25 0.26 0.41 0.82 7.15 6.40 0.18 0.05 7.44 7.40 13.43 13.30 3.53 0.35 0.40 0.73 7.32 6.50 0.20 0.05 7.40 7.40 13.56 13.50 4.00 0.29 0.40 0.75 Red Blood Cell 4.82 4.79 0.42 4.83 4.82 0.37 4.83 4.83 0.38 4.81 4.80 0.40 4.83 4.82 0.40 4.84 4.83 0.39 4.81 4.80 0.38 4.83 4.80 0.39 4.84 4.81 0.37 4.84 4.81 0.39 4.83 4.81 0.39 p. 42 Women (Female, >*18Y0) Page 14 Women (Female, >=18YO) Tabular (Numeric) Summary for Clinical Lab Values within Population C8/PF0A Deciles, Stratified by Age & Gender Population Decile Group - C8 (PFO A ) 1 2 4 4 5 *> f # a 1(J Total Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation A-G Ratio (Final A F P Tumor Marker, Recoded Value) Serum ( ng-mL) 1.50 1.50 6.78 2.00 0.24 28.83 1.51 1.50 4.60 2.00 0.23 18.40 1.51 1.50 4.77 2.00 0.22 18.78 1.51 1.50 4.62 2.00 0.23 23.12 1.51 1.50 5.58 2.00 0.23 92.43 1.51 1.50 3.77 2.00 0.22 13.65 1.51 1.50 3.81 2.00 0.23 14.72 1.52 1.50 3.33 2.00 0.22 10.11 1.51 1.50 3.21 2.00 0.22 7.40 1.53 1.50 3.06 2.00 0.23 8.12 1.51 1.50 4,52 2.00 0.23 33.76 Albumin, Serum ( gdL) 4.31 4.30 0.34 4.35 4.40 0.30 4.37 4.40 0.30 4.36 4.40 0.29 4.38 4.40 0.29 4.38 4.40 0.30 4.38 4.40 0.29 4.38 4.40 0.29 4.38 4.40 0.28 4.41 4.40 0.27 4.37 4.40 0.30 Alkaline Phosphatase, Serum ( IU-L) 82.54 78.00 Antinuclear Antibodies Direct ( U- ALT (S G P T ) ( IU-L) mL) 19.96 17.00 38.71 27.00 A S T (SG O T) ( IU-L) 20.34 18.00 28.89 15.51 63.51 11.30 83.29 79.00 20.29 17.00 40.23 28.00 20.62 19.00 27.79 82.71 78.00 12.84 20.75 17.00 74.62 40.49 29.00 8.75 20.94 19.00 27.34 14.53 69.15 10.10 83.65 80.00 20.84 18.00 42.37 28.00 21.16 19.00 30.01 83.28 79.00 35.10 14.01 20.71 17.00 12.61 76.19 44.55 29.00 90.46 9.89 21.39 19.00 12.35 83.22 79.00 27.09 82.64 78.00 20.83 18.00 13.70 21.18 18.00 41.60 29.00 61.58 44.09 30.00 21.46 19.00 10.17 21.74 20.00 27.87 26.94 70.51 20.09 83.62 79.00 21.56 18.00 49.92 30.00 22.25 20.00 31.39 16.37 118.30 11.77 83.27 79.00 20.74 18.00 46.08 30.00 21.66 20.00 29.93 11.85 83.39 9.14 84.38 81.00 21.94 19.00 49.01 29.00 22.28 20.00 27.39 15.18 109.70 9.58 83.21 79.00 20.80 17.00 43.24 29.00 21.29 19.00 29.34 15.77 82.09 11.66 Baso (Absolute) ( x10e3-uL) 0 .0 2 0 .0 0 0 .0 4 0 .0 2 0 .0 0 0 .0 4 0 .0 2 0 .00 0 .04 0 .03 0 .00 0 .04 0 .02 0 .00 0 .0 4 0 .0 3 0 .0 0 0 .0 4 0 .0 3 0 .0 0 0 .05 0 .03 0 .00 0 .04 0 .03 0 .00 0 .04 0 .0 3 0 .0 0 0 .04 0 .0 3 0 .0 0 0 .0 4 0.26 0.00 0.44 0.25 0.00 0.44 0.27 0.00 0.45 0.29 0.00 0.47 0.29 0.00 0.46 0.31 0.00 0.47 0.32 0.00 0.48 0.32 0.00 0,47 0.31 0.00 0.46 0.29 0.00 0.46 0.29 0.00 0.46 2009 W est Virginia University School of Medicine p. 43 Women (Female, >~18Y0) Page 15 Women (Female, >=18YO) Population Decile Group - C8 (PFO A ) 1 2 3 4 5 6 7 8 9 10 Total Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Bilirubin, Direct ( mg-dL) 0.10 0.09 Bilirubin, Total ( mg-dL) 0.35 0.30 BUN ( mg-dL) 12.78 12.00 BUN-Creatinine Ratio (Final Recoded Value) 15.69 15.00 Calcium, Serum ( mg-dL) 9.72 9.70 C an cer Antigen (CA-125) ( U-mL) C E A ( ng-mL) 16.47 12.90 1.25 0.80 Chloride, Serum ( mmol-L) 103.79 104.00 Cholesterol, Total ( mg-dL) 193.64 189.00 0.05 0.21 5,57 5.07 0.40 17.12 4.62 2.46 42.57 0.10 0.10 0.37 0.30 12.90 12.00 15.80 15.00 9.77 9.80 27.92 12.50 1.25 0.80 103.66 104.00 196.22 191.00 0.05 0.21 4,88 5.04 0.40 750.79 3.85 2.43 42.29 0.11 0.10 0.38 0.30 12.97 12.00 15.79 15.00 9.79 9.80 14.66 12.20 1.28 0.80 103.52 104.00 197.95 194.00 0.05 0.22 4.87 4.82 0.39 10.94 2.21 2.41 41.70 0.11 0.10 0.38 0.30 13.35 13.00 16.04 15.50 9.81 9.80 14.81 12.20 1.22 0.90 103.43 104.00 199.29 195.00 0.05 0.23 4.99 5.00 0.40 19.81 2.63 2.46 41.72 0.11 0.10 0.38 0.30 13.34 13.00 16.06 16.00 9.82 9.80 15.15 12.30 1.52 0.90 103.35 103.00 200.55 197.50 0.05 0.21 5.03 4.94 0.40 21.86 11.48 2.56 41.32 0.11 0.10 0.38 0.30 13.61 13.00 16.23 16.00 9.82 9.80 14.74 12.10 1.28 0.90 103.33 103.00 202.81 199.00 0.05 0.21 5.17 5.01 0.41 14.19 1.87 2.56 43.12 0.11 0.10 0.38 0.30 13.94 13.00 16.44 16.00 9.83 9.80 14.77 12.20 1.52 0.90 103.10 103.00 203.21 200.00 0.05 0.21 5.72 5.08 0.39 11.59 8.82 2.52 43.07 0.11 0.10 0.39 0.30 13.91 13.00 16.45 16.00 9.84 9.80 14.70 12.10 1.49 0.90 102.97 103.00 204.69 200.00 0.05 0.22 5.39 5.11 0.42 11.88 5.33 2.60 42.41 0.11 0.10 0.38 0.30 13.86 13.00 16.36 16.00 9.84 9.80 14.77 12.10 1.41 1.00 103.13 103.00 204.20 201.00 0.06 0.21 5.02 4.98 0.40 14.87 1.72 2.62 41.64 0.11 0.10 0.38 0.30 14.12 13.00 16.45 16.00 9.88 9.90 14.41 11.80 1.62 1.10 102.81 103.00 208.27 205.00 0.05 0,20 5.33 4.95 0.41 14.72 3.03 2.69 43.34 0.11 0.10 0.38 0.30 13.41 13.00 16.09 16.00 9.80 9.80 16.52 12.30 1.37 0.90 103.35 103.00 200.44 196.00 0.05 0.21 5.23 5.01 0.40 255.27 5.45 2.54 42.52 2009 West Virginia University School of Medicine p. 44 Women (Female, >-18Y0) Page 16 Women (Female, >=18YO) Population Decile Group - C8 (PFO A ) 1 2 3 4 5 6 7 8 9 10 Total Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Cortisol ( ug-dL) 12.33 11.00 C-Reactive Protein, Creatinine, Serum ( Quant ( mg-L) mg-dL) Eos ( %) 4.91 2.50 0.83 0.80 2.02 2.00 Eos (Absolute) ( x10e3-uL) 0.16 0.10 Folates (Folic Acid), Estradiol ( pg-mL) Serum ( ng-ml) 441.04 43.50 17.52 14.50 Free Testosterone, Direct ( pg-mL) 0.76 0.60 Free inyroxine Index (Final Recoded Value) 2.36 2.30 6.40 8.08 0.36 1.68 0.13 2311.97 10.31 1.40 0.50 12.51 11.10 4.83 2.50 0.82 0.80 2.02 2.00 0.15 0.10 262.21 36.00 17.76 14.70 0.75 0.60 2.40 2.40 6.70 8.24 0.18 1.61 0.12 1720.56 10.32 0.88 0.51 12.42 11.20 4.73 2.40 0.82 0.80 2.02 2.00 0.15 0.10 264.31 34.00 17.55 14,70 0.79 0.60 2.38 2.40 6.39 7.76 0.16 1.52 0.11 1563.34 10.25 0.84 0.49 12.37 11.20 4.74 2.50 0.84 0.80 2.04 2.00 0.15 0.10 206.20 31.00 17.85 14.60 0.72 0.60 2.39 2.40 6.49 8.24 0.25 1.63 0.13 1310.70 10.56 0.65 0.53 12.23 11.00 4.49 2.40 0.64 0.80 2.04 2.00 0.15 0.10 176.27 31.00 18.30 14.95 0.78 0.60 2.40 2.40 6.58 6.87 0.19 1.60 0.12 1318.58 10.61 1.02 0 .5 0 12.17 10.90 4.39 2.30 0.84 0.80 2.13 2.00 0.16 0.10 143.16 29.00 18.44 15.30 0.77 0.60 2.40 2.40 6.32 6.45 0.17 1.65 0.14 1053.12 10.48 1.70 0 .4 6 12.10 11.10 4.35 2.30 0.85 0.80 2.11 2.00 0.16 0.10 148.35 27.00 18.73 15.50 0.72 0.60 2.39 2.40 6.00 7.40 0.19 1.69 0.13 1023.75 10.66 0.69 0 .4 8 12.15 11.10 3.98 2.10 0.85 0.80 2.09 2.00 0.15 0.10 139.30 26.00 19.26 16.00 0.73 0.60 2.44 2.40 6.02 5.66 0.18 1.54 0.11 1162.83 10.77 0.78 0 .5 0 11.97 10.90 6.07 4.22 2.10 7.62 0.85 0.80 0.18 2.20 2.00 1.78 0.16 0.10 0.13 100.37 26.00 649.82 19.93 16.35 10.82 0.67 0.50 0.72 2.43 2.40 0.51 11.78 11.00 4.07 2.00 0.86 0.80 2.13 2.00 0.16 0.10 84.43 24.00 20.52 17.20 0.67 0.50 2.41 2.40 5.59 6.71 0.24 1.59 0.12 648.83 10.91 0.77 0.50 12.23 11.00 4.51 2.30 0.84 0.80 2.07 2.00 0.16 0.10 212.99 31.00 18.46 15.20 0.74 0.60 2.40 2.40 6.30 7.43 0.22 1.63 0.13 1448.15 10.59 1.02 0.50 2009 West Virginia University School of Medicine p. 45 Women (Female, >~18Y0) Page 17 Women (Female, >=18YO) Population Decile Group - C8 (PFO A ) 1 2 3 4 6 6 7 8 9 10 Total Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation G G T ( IU-L) 23.10 16.00 Globulin, Total ( gd l) 2.92 2.90 Glucose, Serum ( m g -d l) 101.61 93.00 HDL Cholesterol ( mg-dL) Hematocrit ( % ) 53.20 51.00 39.94 40.10 Hemoglobin ( g-dL) 13.42 13.60 Immunoglobulin A, Qn, Serum ( mg-dl) 217.05 202.00 Immunoglobulin E , Total ( lU-mL) 68.54 16.00 31.33 0.38 38.97 14.31 3.67 1.29 98.89 246.80 24.83 17.00 2.94 2.90 101.03 93.00 54.00 52.00 40.54 40.70 13.65 13.70 217.52 203.00 67.31 15.00 35.29 0.37 37.79 14.32 3.25 1.10 98.13 231.32 24.21 17.00 29.61 2.94 2.90 0.36 101.46 93.00 35.19 54.44 53.00 14.53 40.73 40.80 3.19 13.72 13.80 1.08 216.30 200.00 98.79 55.28 15.00 145.39 24.87 17.00 32.64 2.94 2.90 0.37 101.32 93.00 35.91 54.36 53.00 14.35 40.78 40.80 3.26 13.73 13.80 1.11 215.28 200.00 98.02 62.23 14.00 228.02 24.53 17.00 27.33 2.95 2.90 0.36 100.13 93.00 30.69 54.61 53.00 14.58 40.82 40.90 3.30 13.73 13.80 1.13 215.42 199.00 99.09 63.11 14.00 250.67 24.21 17.00 25.57 2.94 2.90 0.35 101.30 93.00 35.48 55.40 54.00 14.66 40.91 41.00 3.33 13.76 13.80 1.11 211.45 195.00 99.30 64.69 14.00 281.07 25.58 17.00 2.94 2.90 101.39 94.00 55.48 54.00 40.86 40.90 13.74 13.80 212.06 197.00 67.28 15.00 39.51 0.36 32.15 14.76 3.26 1.11 101.84 261.61 25.52 17.00 2.92 2.90 100.12 94.00 55.98 54.00 41.01 41.00 13.78 13.80 208.14 192.00 56.56 14.00 31.51 0.36 28.87 15.07 3.31 1.12 105.55 157.75 25.61 17.00 40.96 2.95 2.90 0.36 100.82 94.00 29.65 56.19 54.00 14,61 41.01 41.00 3.25 13.79 13.80 1.09 214.50 196.00 112.15 50.42 13.00 184.56 26.73 18.00 2.93 2.90 102.33 95.00 56.31 54.00 41.02 41.10 13.81 13.80 211.54 195.00 62.67 13.00 36.28 0.37 31.17 15.27 3.36 1.15 111.69 233.88 24.79 17.00 2.94 2.90 101.16 93.00 54.85 53.00 40.71 40.80 13.70 13.70 214.25 198.00 62.25 14.00 33.14 0.37 34,21 14.64 3.35 1.14 101.96 226.84 2009 W est Virginia University School of Medicine p. 46 Women (Female, >-18Y0) Page 18 t Women (Female, >=18YO) Population Decile Group - C8 (PFO A ) Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Immunoglobulin G , Qn, Scrum ( mg-dl) 1062.24 1043.00 265.75 1068.15 1047.00 248.02 1063.10 1043.00 248.19 1059.83 1039.00 253.38 1055.02 1028.00 251.13 1042.23 1020.00 235.82 1037.47 1016.00 248.61 1029.35 997.00 258.12 1037.79 1015.00 246.25 1025.85 1002.00 255.99 1049.95 1028.00 252.21 Immunoglobulin M, Qn, Serum ( mg-dl) 140.28 123.00 156.28 137.43 122.00 86.07 135.67 121.00 80.90 133.95 117.00 86.86 134.24 118.00 83.64 136.06 119.00 92.69 130.35 114.00 84.55 133.73 114.00 89.46 132,48 116.00 93.00 133.83: 113.00 128.28 135.16 118.00 103.35 Insulin, Fasting ( ulU-m l) 19.97 11.80 26.83 20.70 11.90 30.48 20.35 12.20 28.31 20.09 12.30 23.80 19.84 11.50 31.20 20.18 11.20 32.06 18.76 11.70 23.23 18.51 11.20 26.12 18.19 11.10 24.11 17.35 10.30 20.96 19.51 11.60 27.14 Insulin-like Growth Factor I ( ng-mL) 164.08 151.00 Iron, Serum ( ugd l) LDH ( IU-L) 75.30 71.00 167.32 162.00 74.79 35.29 35.30 157.56 142.00 79.62 75.00 169.05 165.00 73.63 34.20 40.60 155.79 142.00 80.24 76.00 168.46 164.00 70.73 34.07 33.98 149.95 136.001 80.12 76.00 169.54 165.00 70.70 33.38 33.41 149.67 135.00 80.79 77.00 170.96 166.00 72.47 33.60 50.83 146.29 133.00 81.03 76.00 172.48 168.00 69.67 33.59 35.67 141.00 128.00 82.45 79.00 172.60 168.00 65.11 33.64 33.36 138.67 125.00 83.61 79.00 173.96 169.00 66.36 34.47 34.57 136.55 123.00 81.82 78.00 173.62 170.00 63.51 32.68 44.94 130.97 119.00 81.39 78.00 177.47 174.00 58.56 31.02 36.41 148.55 135.00 80.32 76.00 171.13 167.00 70.07 33.82 38.31 IO L Cholesterol ( Calculated) 109.40 106.00 Lymphs ( %) 28.97 29.00 Lymphs (Absolute) ( x10e3-ul) 2.13 2.10 34.88 7.64 0.85 110.74 108.00 29.23 29.00 2.13 2.00 33.49 7.68 0.73 111.92 109.00 29.46 29.00 2.16 2.10 34.16 7.57 1.81 112.63 109.00 29.54 29.00 2.14 2.10 35.08 7.35 0.66 113.86 110.00 29.46 29.00 2.15 2.00 34.81 7.69 0.93 114.77 111.00 29.48 29.00 2.13 2.00 35.82 7.29 0.68 114.18 111.00 29.53 29.00 2.14 2.10 34.44 7.64 0.74 115.87 112.00 29.81 29.00 2.12 2.00 36.24 7.41 0.73 114.58 111.00 29.65 30.00 2.10 2.00 34.59 7.51 0.68 117.12 113.00 29.68 29.00 2.18 2.00 36.15 7.60 1.75 113.16 110.00 29.45 29.00 2.14 2.00 34.98 7.55 1.03 2009 West Virginia University School of Medicine p. 47 Women(Female, >=18Y0) Page19 Women (Female, >=18YO) Population Decile Group - C8 (PFO A ) 1 2 3 4 5 6 7 8 9 10 Total Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation M a g n e siu m , Serum ( mg-dL) MCH ( pg) 1.98 2.00 30.18 30.50 M CHC ( g-dL) MCV ( fL) 33.60 33.70 89.79 90.00 M onocytes(A bsolute) Monocytes ( %) ( x10e3-uL) 5.68 6.00 0.42 0.40 Neutrophils ( % ) 63.06 63.00 Neutrophils (Absolute) ( x10e3- uL) 4.84 4.60 Phosphorus, Serum ( mg-dL) 3.64 3.60 Platelets ( x10e3uL) 299.33 290.00 0.17 2.31 0.77 5.89 1.97 0.16 8.66 1.85 0.59 73.95 1.99 2.00 30.43 30.60 33.67 33.70 90.37 91.00 5.75 6.00 0.42 0.40 62.74 63.00 4.78 4.40 3.62 3.60 294.88 290.00 0.17 1.95 0.68 5.08 2.00 0.16 8.77 1.89 0.56 69.57 1.99 2.00 30.50 30.60 33.69 33.70 90.55 91.00 5.85 6.00 0.42 0.40 62.40 63.00 4.73 4.40 3.64 3.60 293.45 288.00 0.16 1.78 0.64 4.66 2.01 0.16 8,61 1.80 0.56 67.09 2.00 2.00 30.52 30.60 33.68 33.70 90.64 91.00 5.83 6.00 0.42 0.40 62.30 62.00 4.71 4.40 3.65 3.60 295.88 290.00 0.17 1.81 0.64 4.73 1.92 0.16 8.34 1.76 0.58 68.82 2.00 2.00 30.52 30.60 33.63 33.70 90.76 91.00 5.83 6.00 0.42 0.40 62.38 63.00 4.72 4.40 3.65 3.60 293.54 287.00 0.17 1.93 0.67 5.02 2.03 0.16 8.72 1.81 0.55 68.15 2.01 2.00 30.60 30.70 33.64 33.70 91.01 91.00 5.94 6.00 0.43 0.40 62.13 62.00 4.66 4.40 3.65 3.70 295.01 290.00 0.17 1.79 0.63 4.75 2.00 0.16 8.22 1.75 0.54 70.80 2.01 2.00 30.71 30.80 33.64 33.70 91.33 91.00 6.01 6.00 0.43 0.40 62.03 62.00 4.66 4.40 3.67 3.70 292.02 288.00 0.17 1.77 0.65 4.67 2.09 0.17 8.69 1.75 0.55 67.85 2.02 2.00 30.76 30.90 33.60 33.60 91.58 92.00 6.02 6.00 0.43 0.40 61.75 62.00 4.55 4.30 3.68 3.70 291.10 285.00 0.17 1.84 0.64 4.89 2.05 0.17 8.44 1.68 0.53 67.61 2.02 2.00 30.69 30.80 33.61 33.60 91.34 91.50 5.99 6.00 0.42 0.40 61.85 62.00 4.55 4.30 3.69 3.70 292.26 285.00 0.16 1.82 0.64 4.83 2.03 0.16 8.52 1.65 0.53 72.75 2.02 2.00 30.80 30.90 33.65 33.70 91.53 92.00 5.96 6.00 0.43 0.40 61.94 62.00 4.61 4.30 3.73 3.70 291.70 285.00 0.16 1.88 0.65 4.94 1.99 0.17 8.45 1.71 0.56 68.70 2.00 2.00 30.54 30.70 33.64 33.70 90.80 91.00 5.87 6.00 0.42 0.40 62.32 63.00 4.70 4.40 3.66 3.70 294.25 288.00 0.17 1.93 0.67 5.04 2.01 0.16 8.56 1.78 0.56 69.77 2009 West Virginia University School of Medicine p. 48 Women (Female, >-l8Y0) Page 20 Women (Female, >=18YO) Population Decile Group - C8 (PFO A ) Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Potassium, Serum ( mmol-L) 4.08 4.10 0.32 4.07 4.10 0.32 4.08 4.10 0.34 4.09 4.10 0.34 4.10 4.10 0.33 4.12 4.10 0.34 4.11 4.10 0.34 4.13 4.10 0.36 4.14 4.10 0.36 4.16 4.10 0.37 4.10 4.10 0.34 Protein, Total, Prolactin ( ng-mL) Serum ( g-dL) ROW ( %) 14.35 8.10 7.24 7.20 14.24 13.90 27.10 0.46 1.56 11.99 8.00 7.29 7.30 13.96 13.70 19.65 0.43 1.33 12.12 7.80 7.31 7.30 13.89 13.60 21.30 0.43 1.21 11.94 7.80 7.31 7.30 13.87 13.70 22.40 0.43 1.19 10.80 7.80 7.32 7.30 13.92 13.70 16.28 0.43 1.24 10.94 7.80 7.32 7.30 13.87 13.70 17.10 0.43 1.12 10.61 7.60 7.32 7.30 13.88 13.60 15.76 0.43 1.17 10.46 7.60 7.31 7.30 13.90 13.70 15.37 0.43 1.22 9.83 7.50 7.32 7.30 13.86 13.70 12.22 0.42 1.18 9.53 7.30 7.33 7.30 13.87 13.60 17.70 0.42 1.23 11.47 7.80 7.30 7.30 13.94 13.70 19.57 0.43 1.28 Red Blood Cell Count ( x10e6-uL) 4.46 4.47 0.40 4.50 4.50 0.37 4.51 4.51 0.36 4.51 4.52 0.37 4.51 4.52 0.37 4.51 4.51 0.39 4.48 4.49 0.38 4.49 4.50 0.38 4.50 4.51 0.38 4.49 4.49 0.38 4.49 4.50 0.38 Sodium, Serum ( mmol-L) T3 Uptake ( %) 140.39 140.00 29.23 30.00 2.18 4.09 140.48 141.00 29.07 30.00 2.17 3.89 140.53 141.00 29.03 29.00 2.13 3.85 140.60 141.00 29.00 30.00 2.19 3.82 140.58 141.00 29.17 29.00 2.28 3.65 140.66 141.00 29.26 30.00 2.28 3.66 140.54 141.00 29.21 30.00 2.19 3.64 140.57 141.00 29.36 30.00 2.36 3.61 140.69 141.00 29.36 30.00 2.34 3.49 140.62 141.00 29.41 30.00 2.35 3.39 140.55 141.00 29.20 30.00 2.24 3.75 Testosterone, Serum ( ng-dL) 41.11 38.00 22.55 40.49 37.00 28.12 40.88 38.00 23.16 39.11 37.00 18.47 39.90 37.00 25.00 39.05 37.00 21.68 38.08 36.00 19.39 38.03 36.00 19.28 37.33 35.00 20.44 37.03 35.00 20.81 39.30 36.00 22.33 Thyroxine (T4) ( ngdL) 8.21 8.00 1.91 8.37 8.10 1.94 8.31 8.10 1.90 8.36 8.10 1.96 8.34 8.10 1.91 8.33 8.10 1.85 8.30 8.10 1.86 8.41 8.20 1.89 8.38 8.20 1.87 8.28 8.10 1.87 8.32 8.10 1.90 2009 W ast Virginia University School of Medicine p. 49 Men (Male, >=18Y0) Page 21 Men (Male, >*18YO) Tabular (Numeric) Summary for Clinical Lab Values within Population C8/PF0A Deciles, Stratified by Age & Gender Population Decile Group - C8 (PFO A ) 1 Mean Median Std. Deviation A-G Ratio (Final Recoded Value) 1.59 1.60 AFP Tumor Marker, Serum ( ng-mL) 2.45 2.00 Albumin, Serum ( g-dL) 4.40 4.40 Alkaline Phosphatase. Serum ( IU-L) A LT (S G P T ) ( IUL) 86.70 28.46 82.00 25.00 Antinuclear Baso Antibodies A S T (S G O T ) ( (Absolute) ( Direct ( U -m l) IU-L) x10e3-uL) 38.02 26.00 24.41 22.00 0.02 0.00 Bilirubin, Direct ( Basos( %) mg-dL) 0.26 0.00 0.13 0.11 Bilirubin, Total ( mg-dL) 0.47 0.40 BUN ( mg-dL) 16.20 15.00 0.27 1.01 0.34 32.12 17.99 47.67 11.64 0.04 0.44 0.07 0.32 7.34 2 Mean 1.61 2.50 4.49 86.54 31.37 37.96 25.98 0.02 0.25 0.13 0.50 15.33 Median 1.60 2.00 4.50 83.00 26.00 27.00 22.00 0.00 0.00 0.12 0.40 14.00 Std. Deviation 0.24 1.06 0.29 31.09 36.36 56.61 26.23 0.04 0.44 0.09 0.29 5.46 3 Mean 1.62 2.55 4.51 85.22 30.46 37.30 24.83 0.02 0.26 0.13 0.50 14.97 Median 1.60 2.00 4.50 82.00 26.00 27.00 22.00 0.00 0.00 0.12 0.40 14.00 Std. Deviation 0.24 2.20 0.29 26.14 21.08 56.66 12.40 0.04 0.44 0.06 0.29 5.10 4 Mean 1.63 2.56 4.53 84.78 32.18 37.01 25.55 0.02 0.28 0.14 0.52 14.99 Median 1.60 2.00 4.50 82.00 26.00 27.00 23.00 0.00 0.00 0.12 0.40 14.00 Std. Deviation 0.24 1.29 0.29 25.79 34.52 52.36 16.57 0.04 0.45 0.25 0.46 4.65 5 Mean 1.62 12.47 4.54 85.28 31.69 38.13 25.32 0.02 0.27 0.13 0.51 15.15 Median 1.60 2.00 4.50 82.00 26.00 28.00 23.00 0.00 0.00 0.12 0.40 15.00 Std. Deviation 0.24 524.43 0.28 23.82 20.68 62.32 11.29 0.04 0.45 0.06 0.29 4.88 6 Mean 1.62 2.54 4.53 84.08 31.24 40.19 25.77 0.03 0.30 0.14 0.51 15.45 Median 1.60 2.00 4.50 80.00 26.00 28.00 23.00 0.00 0.00 0.12 0.40 15.00 Std. Deviation 0.24 1.43 0.29 31.75 26.21 77.25 18.61 0.04 0.46 0.15 0.35 5.13 7 Mean 1.62 2.57 4.53 84.02 31.08 40.43 25.61 0.03 0.30 0.13 0.52 15.28 Median 1.60 2.00 4.50 81.00 26.00 30.00 23.00 0.00 0.00 0.12 0.40 15.00 Std. Deviation 0.24 1.26 0.29 25.89 20.23 59.23 15.69 0.04 0.47 0.06 0.29 5.18 8 Mean 1.61 2.58 4.52 83.56 30.73 42.44 25.36 0.03 0.33 0.13 0.52 15.30 Median 1.60 2.00 4.50 81.00 26.00 30.00 23.00 0.00 0.00 0.12 0.40 15.00 Std. Deviation 0.24 1.25 0.29 23.80 19.29 73.78 14.03 0.05 0.48 0.06 0.30 4.80 9 Mean 1.61 2.60 4.53 83.38 30.55 39.85 25.37 0.03 0.33 0.13 0.51 15.40 Median 1.60 2.00 4.50 80.00 26.00 29.00 23.00 0.00 0.00 0.12 0.40 15.00 Std. Deviation 0.23 1.28 0.27 26.02 18.49 51.89 11.15 0.05 0.47 0.06 0.28 4.59 10 Mean 1.62 2.61 4.53 84.04 31.64 41.48 25.65 0.03 0.32 0.13 0.51 15.58 Median 1.60 2.00 4.50 81.00 27.00 29.00 23.00 0.00 0.00 0.12 0.40 15.00 Std. Deviation 0.24 1.06 0.27 24.02 19.67 58.48 11.54 0.05 0.47 0.06 0.29 4.83 Total Mean Median Std. Deviation 1.62 1.60 0.24 3.60 2.00 169.61 4.52 4.50 0.29 84.58 81.00 26.81 31.04 26.00 23.92 39.47 28.00 60.89 25.42 23.00 15.19 0.03 0.00 0.04 0.29 0.00 0.46 0.13 0.12 0.11 0.51 0.40 0.32 15.34 15.00 5.13 <38009 West Virginia University School of Medicine p. 50 Men (Male, >=18Y0) Page 22 4 Men (Male, >=18Y0) Population D ecle Group - C8 (PFO A ) 1 Mean Median Std. Deviation 2 Mean Median Std. Deviation 3 Mean Median Std. Deviation 4 Mean Median Std. Deviation 5 Mean Median Std. Deviation 6 Mean Median Std. Deviation 7 Mean Median Std. Deviation 8 Mean Median Std. Deviation 9 Mean Median Std. Deviation 10 Mean Median Std. Deviation Total Mean Median Std. Deviation BUN-Creatinine Ratio (Final Calcium, Serum ( Cancer Antigen Chloride, Serum Recoded Value) m g -d l) (CA-125) ( U-mL) C E A ( ng-mL) ( mmol-L) 14.81 9.79 13.33 1.67 103.13 14.00 9.80 10.60 1.30 103.00 Cholesterol, Total ( mg-dL) 188.39 185.00 Cortisol ( ug-dL) 13.02 12.30 C-Reactfve Protein, Quant ( mg-L) 4.30 1.80 Creatinine, Eos (Absolute) ( Serum ( mg-dl) Eos ( %) x10e3-uL) 1.14 2.50 1.00 2.00 0.19 0.20 4.42 0.41 12.64 1.69 2.77 44.02 5.33 8.26 0.77 1.81 0.15 14.75 14.00 9.85 9.80 12.41 10.70 1.53 103.05 189.19 1.30 103.00 187,00 13.31 12.70 4.08 1.70 1.05 1.00 2.42 2.00 0.18 0.10 4.32 0.39 8.66 1.24 2.45 41.13 5.45 10.94 0.36 1.80 0.14 14.44 14.00 9.87 9.90 12.64 10.70 1.51 103.13 191.66 1.20 103.00 188.00 13.32 12.90 3.39 1.60 1.05 2.45 1.00 2.00 0.18 0.10 4,14 0.37 8.70 1.24 2.36 43,47 5.50 7.17 0.24 1.86 0.15 14.42 14.00 9.89 9.90 13.88 10.70 3.15 1.30 103.05 103.00 192.90 191.00 13.42 12.70 3.25 1.50 1.05 1.00 2.41 2.00 0.18 0.10 4.11 0.38 73.28 62.47 2.37 42.00 5.61 8.12 0.24 1.76 0.14 14.52 14.00 9.89 9.90 13.21 11.00 1.49 103.07 195.14 1.20 103.00 191.00 13.50 12.90 3.19 1.50 1.05 2.38 1.00 2.00 0.18 0.10 3.93 0.37 22.52 1.25 2.42 44.09 5.59 7.11 0.19 1.69 0.13 14.72 14.00 9.87 9.90 13.05 10.80 1.82 102.98 192.45 1.20 103.00 188.00 13.24 12.70 3.16 1.40 1.06 2.41 1.00 2.00 0.18 0.10 4.14 0.38 15.51 14.59 2.48 43.16 5.54 7.72 0.21 1.73 0.13 14.52 14.00 9.88 9.90 13.18 10.70 1.73 102.88 195.74 1.30 103.00 193.00 13.11 12.50 2.99 1.40 1.06 2.36 1.00 2.00 0.17 0.10 3.93 0.39 20.14 9.33 2.54 44.01 5.55 6.82 0.21 1.69 0.12 14.58 14.00 4.03 9.88 9.90 0.38 13.00 10.90 13.39 1.53 102.75 194.47 1.20 103.00 191.00 1.52 2.43 41.37 13.04 12.50 5.51 2.98 1.40 6.41 1.06 1.00 0.21 2.48 2.00 1.86 0.18 0.10 0.15 14.71 14.00 9.88 9.90 12.64 10.90 1.63 1.30 102.83 103.00 196.86 194.00 12.74 12.20 2.84 1.40 1.06 2.44 1.00 2.00 0.18 0.10 3.90 0.38 10.13 1.92 2.48 40.88 5.38 5.79 0.18 1.80 0.14 14.75 14.00 9.89 9.90 12.92 11.00 1.55 1.30 102.72 103.00 199.15 197.00 12.76 12.10 2.81 1.30 1.07 1.00 2.49 2.00 0.18 0.10 4.06 0.38 8.55 1.18 2.45 41.34 5.46 6.41 0.20 1.73 0.13 14.62 14.00 9.87 9.90 13.03 10.80 1.77 1.30 102.94 103.00 194.12 191.00 13.13 12.50 3.22 1.50 1.06 1.00 2.43 2.00 0.18 0.10 4.08 0.38 27.20 20.89 2.47 42.59 5.50 7.41 0.29 1,77 0.14 2009 West Virginia University School of Medicine p. 51 Men (Male, >*18Y0) Page 23 Men (Male, >=18Y0) Population Decile Group - C8 (PFO A ) Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Estradiol ( pgmL) 25.56 24.00 Folates (Folic Acid), Serum ( ng-mL) 17.82 14.60 Free Testosterone, Direct ( pg-m l) 9.68 9.00 13.15 10.66 4.82 24.75 24.00 17.13 13.70 9.94 9.30 9.44 10.12 4.11 24.82 24.00 16.62 13.80 10.16 9.60 9.58 9.66 4.55 25.20 24.00 16.91 14.30 10.42 9.80 9.71 9.80 4.85 25.14 24.00 17.14 14.40 10.31 9.90 9.41 9.89 4.03 25.23 24.00 17,28 14.15 10.44 9.80; 9.62 10.08 4.76 29.04 24.00 17.22 14.40 10.35 9.80 203.00 9.66 4.53 24.93 24.00 17.35 14.20 10.40 9.90 9.36 10.06 4.43 25.39 24.00 18.10 15.10 10.19 9.70 9.94 10.22 4.26 25.89 25.00 18.31 15.20 10.11 9.60 9.29 10.10 4.06 25.64 24.00 17.41 14.40 10.23 9.70 66.97 10.02 4.44 Free Thyroxine Index (Final Recoded Value) G G T ( IU-L) 2.37 2.30 39.99 27.00 0.47 54.56 2.42 2.40 40.63 27.00 0.48 82.21 2.41 2.40 36.84 26.00 0.45 45.57 2.42 2.40 36.85 26.00 0.48 47.34 2.41 2.40 37.72 27.00 0.46 41.93 2.40 2.40 39.01 26.00 0.50 80.87 2.41 2.40 37.42 26.00 0.48 49.47 2.42 2.40 37.60 26.00 0.44 50.72 2.42 2.40 35.58 27.00 0.44 36.79 2.40 2.40 37.42 28.00 0.49 36.06 2.41 2.40 37.70 27.00 0.47 53.34 Globulin, Total ( B-dU) Glucose, Serum ( mg-dL) HDL Cholesterol ( mg-dL) 2.83 2.80 117.95 100.00 43.36 42.00 0.42 56.00 11.60 2.83 2.80 111.76 99.00 43.75 42.00 0.36 47.73 11.65 2.84 2.80 107.28 98.00 43.71 42.00 0.36 37.98 11.37 2.83 2.80 106.10 97.00 43.69 42.00 0.36 34.28 11.67 2.85 2.80 106.25 97.00 43.89 42.00 0.36 38.14 11.09 2.85 2.80 106.50 97.00 43.98 42.00 0.38 37.81 11.99 2.85 2.80 107.68 98.00 43.94 42.00 0.36 38.96 11.65 2.86 2.80 106.99 97.00 43.71 42.00 0.35 37.74 11.29 2.85 2.80 106.83 98.00 44.53 43.00 0.35 37.26 11.84 2.84 2.80 106.33 97.00 44.57 43.00 0.36 35.93 11.89 2.84 2.80 0.37 107.80 98.00 39.63 43.96 42.00 11.62 Hematocrit ( %) 44.81 45.30 4.04 45.46 45.70 3.37 45.56 45.80 3.33 45.71 45.90 3.32 45.79 45.90 3.36 45.53 45.80 3.43 45.78 45.90 3.36 45.76 45.80 3.24 45.69 45.80 3.22 45.61 45.70 3.29 45.61 45.80 3.38 Hemoglobin ( gdU) 15.15 15.30 1.40 15.40 15.50 1.16 15.44 15.50 1.15 15.50 1560 1.13 15.51 15.60 1.14 15.44 15.50 1.17 15.50 15.60 1.14 15.48 15.50 1.11 15.47 15.50 1.10 15,46 15.50 1.12 15.45 15.50 1.16 Immunoglobulin A, Qn, Serum ( mg-dL) 237.76 218.50 122.04 236.86 216.00 115.60 234.06 217.00 105.95 230.69 215.00 108.89 230.56 214.00 105.94 227.05 211.00 106.64 229.14 212.00 109.04 228.09 213.00 109.47 226.16 210.00 119.77 224.98 208.50 103.67 229.82 213.00 110.30 <50009 West Virginia University School of Medicine p. 52 Men (Male, >=18Y0) Page 24 Men (Male, >-18Y0) Population Decile Group - C8 (PFO A ) Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation 10 Mean Median Std. Deviation Total Mean Median Std. Deviation Immunoglobulin E , Total ( lU-mL) 115.25 31.00 Immunoglobulin G, Qn, Serum ( mg-dL) 1031,10 1000.50 Immunoglobulin M, Qn, Serum ( mg-dL) Insulin-Like Insulin, Fasting ( Growth Factor I ( u lU -m L) ng-mL) 99.86 86.00 26.37 13.70 150.68 141.00 Iron, Serum ( ug-dL) LDH ( IU-L) 89.57 85.00 171.24 167.00 LDL Cholesterol ( Calculated) 104.20 101.00 Lymphs ( %) 27.97 28.00 Lymphs (Absolute) ( x10e3-uL) 2.07 2.00 Magnesium. Serum ( mg-dL) MCH ( pg) 2.02 30.89 2.00 31.00 305.31 288.67 72.63 40.05 61.09 34.74 34.15 35.01 7.91 0.74 0.16 1 93 124.30 29.00 1045.34 1025.00 103.17 88.00 24.51 13.40 154.58 144.00 93.70 89.00 172.01 167.00 107.44 104.50 28.68 29.00 2.05 2.00 2.03 2.00 30.98 31.00 379.58 242.18 76.32 34.18 62.31 34.92 40.88 34.31 7.42 0.66 0.16 1.60 122.34 30.00 1052.60 1032.00 105.26 92.00 23.67 13.60 156.37 147.00 92.89 89.00 169.82 166.00 108.70 107.00 28.73 28.00 2.09 2.00 2.03 2.00 30.87 30.80 390.73 237.76 68.15 33.72 62.43 33.42 32.47 34.90 7.34 0.68 0.15 1.55 98.26 28.00 1042.90 1019.00 102.04 90.00 23.34 12.95 153.43 146.00 94.53 89.00 171.14 168.00 110.44 108.00 29.02 29.00 2.06 2.00 2.04 2.00 30.88 30.90 266.30 236.73 66.89 33.04 58.00 35.11 33.57 35.74 7.37 0.72 0.15 1.57 108.88 29.00 1042.40 1022.00 104.57 88.00 21.67 12.30 154.33 144.00 95.13 91.00 170.71 167.00 111.68 109.00 28.76 28.00 2.07 2.00 2.04 2.00 30.93 30.90 308.85 239.54 77.07 29.84 60.44 34.23 31.94 36.36 7.49 0.87 0.15 1.53 101.34 28.00 1046.13 1029.00 101.76 88.00 22.23 12.60 150.74 142.00 93.78 89.00 171.08 167.00 109.04 107.00 28.53 28.00 2.01 1.90 2.04 2.00 30.97 31.00 270.33 271.93 76.36 28.74 58.46 34.09 40.37 35.25 7.31 0.64 0.15 1.56 106.00 26.00 1037.83 1014.00 105.88 90.00 22.80 12.90 150.95 139.00 95.18 91.00 171.69 167.00 111.61 109.00 29.00 29.00 2.09 2.00 2.04 2.00 31.01 31.00 323.16 102.86 29.00 239.94 1035.99 1012.00 87.14 105.09 90.00 32.77 22.87 12.60 62.98 145.76 135.00 33.39 94.63 90.00 37.46 171.00 167.00 35.42 111.46 109.00 7.60 28.54 28.00 2.48 2.04 1.90 0.15 2.05 2.00 1.52 31.00 31.00 254.38 239.91 83.94 33.18 60.16 33.11 33.19 35.33 0.98 0.15 1.51 99.62 27.00 316.21 1034.26 1007.00 249.87 104.91 89.00 82.82 21.37 12.10 30.30 143.57 135.00 56.05 94.17 90.00 33.41 171.39 168.00 30.88 112.53 111.00 34.65 28.79 29.00 7.49 2.05 1.90 1.23 2.05 2.10 0.15 31.01 31.00 1.59 93.22 26.00 1028.10 1007.00 102.49 87.00 20.33 11,80 144.21 135.00 95.55 90.00 172.42 169.00 114.25 112.00 28.64 29.00 2.01 1.90 2.05 2.10 31.07 31.00 238.53 241.11 88.22 25.78 56.45 34.35 30.49 34.70 7,31 0.63 0.15 1.55 105.82 28.00 304.74 1039.42 1017.00 247.71 103.67 89.00 78.98 22.64 12.70 31.82 150.03 140.00 59.79 94.15 90.00 34.05 171.27 167.00 34.45 110.61 108.00 35.27 28.70 28.00 7.45 2.05 2.00 1.13 2.04 2.00 30.97 31.00 0.15 1.58 @2009 West Virginia University School of Medicine p. 53 Men (Male, >*18Y0) Page 25 Men (Male, >=18Y0) Population Decile Group - C8 (PFO A ) Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation Mean Median Std. Deviation MCHC ( g-dL) MCV ( fl.) 33.79 33.80 91,42 92.00 0.68 5,15 33.89 33.90 91.48 91.00 0.62 4.42 33.88 33.90 91.14 91.00 0.60 4.22 33.90 33.90 91.14 91.00 0.62 4.26 33.87 33.90 91.37 91.00 0.61 4.20 33.91 33.90 91.37 91.00 0.61 4.27 33.87 33.90 91.62 91.00 0.59 4.21 33.83 33.80 91.68 91.00 0.59 4.19 33.86 33.90 91.62 91.00 0.61 4.35 33.90 33.90 91.71 92.00 0.59 4.30 33.87 33.90 91.47 91.00 0.61 4.33 MonocytesfAbsolu Monocytes ( %) te) ( x10e3-ul) 6.69 7.00 0.49 0.50 2.18 0.19 6.77 7.00 0.48 0.50 2.05 0.17 6.78 7.00 0.49 0.50 2.21 0.18 6.80 7.00 0.48 0.50 2.13 0.18 6.74 7.00 0.48 0.50 2.15 0.18 6.83 7.00 0.48 0.50 2.18 0.18 6.88 0.49 7.00 0.50 2.11 0.17 6.84 0.48 7.00 0.50 2.13 0.18 6.92 7.00 0.49 0.50 2.08 0.18 6.92 7.00 0.49 0.50 2.11 0.28 6.83 0.49 7.00 0.50 2.14 0.19 Neutrophils ( %) 62.59 63.00 8.98 61.88 62.00 8.26 61.78 62.00 8.42 61.49 62.00 8.33 61.85 62.00 8.39 61.93 62.00 8.34 61.45 62.00 8.53 61.80 62.00 8.40 61.52 62.00 8.47 61.63 62.00 8.38 61.75 62.00 8.44 Neutrophils (Absolute) ( x10e3-uL) 4.81 4.50 1.78 4.60 4.30 1.75 4.65 4.30 1.72 4.53 4.20 1.68 4.61 4.30 1.93 4.54 4.20 1.69 4.49 4.20 1.62 4.52 4.20 1.62 4.47 4.20 1.66 4.51 4.20 1.94 4.56 4.30 1.74 Phosphorus, Serum ( mg-dL) 3.53 3.50 0.69 3.50 3.50 0.62 3.50 3.50 0.60 3.49 3.50 0.59 3.49 3.50 0.59 3.52 3.50 0.61 3.52 3.50 0.60 3.50 3.50 0.57 3.53 3.50 0.57 3.55 3.50 0.56 3.51 3.50 0.60 Prostate-Specific Platelets ( Potassium, Prolactin ( ng- Antigen, Serum ( x10e3-uL) Serum ( mmol-L) mL) ng-mL) 269.06 261.00 4.23 4.20 7.78 6.70 1.03 0.70 71.48 0.38 5.70 1.46 259.31 253.00 4.19 4.20 9.09 6.90 1.00 0.60 58.97 0.35 60.63 1.95 262.71 260.00 4.19 4.20 8.08 7.00 0.91 0.60 61.03 0.31 15.63 1.10 261.90 258.00 4.19 4.20 8.41 6.90 1.04 0.60 61.08 0.33 31.87 5.10 261.54 256.00 4.21 4.20 7.62 6.80 1.04 0.70 59.36 0.32 3.96 2.32 258.40 253.00 4.21 4.20 7.80 7.00 1.02 0.60 60.62 0.35 4.25 2.21 257.49 254.00 4.22 4.20 9.17 6.90 1.31 0.60 57.01 0.35 59.21 20.59 258.35 254.00 4.24 4.20 8.52 7.00 1.06 0.70 63.53 0.33 43.85 2.16 257.83 253.00 4.24 4.20 10.06 6.90 1.07 0.70 59.20 0.34 98.23 1.82 258.31 253.00 4.26 4.20 8.44 6.80 1.16 0.70 58.42 0.34 26.47 2.21 260.05 255.00 4.22 4.20 8.53 6.90 1.07 0.70 60.78 0.34 47.03 7.15 Protein, Total, Serum ( g-dL) 7.24 7.20 0.49 7.32 7.30 0.42 7.36 7.30 0.42 7.36 7.40 0.41 7.38 7.40 0.42 7.37 7.40 0.43 7.38 7.40 0.42 7.38 7.40 0.42 7.38 7.40 0.41 7.37 7.40 0.41 7.36 7.40 0.42 2009 West Virginia University School of Medicine p. 54 Men (Male, >=1$Y0) Page 26 Men (Male, >=18Y0) Population Decile Group - C8 (PFO A ) 1 Mean Median Std. Deviation 2 Mean Median Std. Deviation 3 Mean Median Std. Deviation 4 Mean Median Std. Deviation 5 Mean Median Std. Deviation 6 Mean Median Std. Deviation 7 Mean Median Std. Deviation a Mean Median Std. Deviation 9 Mean Median Std. Deviation 10 Mean Median Std. Deviation Total Mean Median Std. Deviation RDW ( %) 14.10 13.80 Red Blood Cell Count ( x10e6- uL) Sodium, Serum ( mmol-L) T3 Uptake ( %) 4.92 4,97 140.62 141.00 32.17 32.00 Testosterone, Thyroxine (T4 ) ( Serum ( ng-dL) ng-dL) 368.81 350.00 7.41 7.40 Triglycerides ( mg-dL) 227.79 169.00 Uric Acid, Serum T SH ( ulU-mL) ( mg-dL) 2.24 1.72 6.17 6.10 Vitamin B 1 2 ( pg-mL) 498.27 435.00 VLDL Cholesterol (Calculated) ( mg-dL) White Blood Cell Count ( x10e3-uL) 34.27 31.00 7.5773 7,3000 1.32 0.49 2.41 3.00 164.51 1.52 204.97 4.60 1.42 293.16 16.86 2.14875 13.81 13.70 4.98 5.01 140.77 141.00 32.13 32.00 370.68 348.50 7.58 7.50 204.45 163.00 2.17 1.66 6.18 6.10 475.49 432.00 34.08 31.00 7.3220 7.0000 0.96 0.42 2.18 3.00 161.00 1.53 157.54 4.07 1.36 244.98 16.96 2.12782 13.75 13.60 5.01 5.03 140.91 141.00 32.07 32.00 369.03 350.00 7.56 7.50 210.52 163.00 2.01 1.69 6.32 6.20 469.84 429.00 33.69 30.00 7.4239 7.1000 0.96 0.41 2.15 3.01 152.36 1.46 184.32 1.43 1.36 224.40 16.91 2.12238 13.72 13.60 5.03 5.04 140.97 141.00 32.04 32.00 374.51 351.00 7.59 7.50 211.81 171.00 2.14 1.70 6.37 6.30 468.99 424.00 34.65 32.00 7.2665 6.9000 0.96 0.41 2.12 3.09 161.57 1.56 159.38 2.61 1.37 214.36 17.26 2.08487 13.70 13.60 5.02 5.05 140.92 141.00 32.08 32.00 367.07 351.00 7.56 7.55 214.90 170.00 2.18 1.71 6.40 6.30 473.37 431,00 34.70 32.00 7.3487 7.0000 0.94 0.42 2.24 3.03 146.26 1.49 193.97 3.58 1.37 221.26 16.84 2.34641 13.73 13.60 4.99 5.03 140.88 141.00 32.15 32.00 379.58 354.00 7.52 7.50 213.40 167.00 2.21 1.73 6.31 6.20 480.26 431.00 34.32 31.00 7.2174 6.9000 1.05 0.43 2.24 3.09 194.50 1.51 183.14 3.08 1.36 255.18 17.05 2.05305 13.68 13.60 5.01 5.03 140.93 141.00 32.13 32.00 368.96 345.00 7.54 7.50 218.79 173.00 2.31 1.72 6.37 6.30 467,49 428.00 35.41 32.00 7.2451 6.9000 0.96 0.42 2.28 3.01 153.02 1.51 189.84 5.09 1.35 201.36 17.14 3.13498 13.67 13.50 5.00 5.01 140.81 141.00 32.09 32.00 373.01 355.00 7.58 7.60 214.44 175.00 2.17 1.74 6.39 6.30 476.98 430.00 35.54 33.00 7.2307 6.9000 0.86 0.40 2.22 2.94 156.51 1.44 158.74 2.46 1.38 242.89 16.95 2.15060 13.70 13.60 5.00 5.02 140.88 141.00 31.90 32.00 371.30 352.00 7.63 7.60 216.17 176.00 2.13 1.75 6.36 6.30 484.29 434.00 35.62 33.00 7.1924 6.9000 0.93 0.40 2.32 2.94 145.68 1.59 169.82 2.05 1.33 258.18 17.14 2.33300 13.67 13.50 4.99 4.99 140.83 141.00 31.96 32.00 380.90 362.00 7.55 7.50 222.71 179.00 2.23 1.78 6.41 6.30 480.92 437.00 35.95 33.00 7.2096 6.9000 0.96 0.41 2.28 2.98 152.22 1.49 174.93 2.90 1.33 232.96 16.97 2.38990 13.73 13.60 5.00 5.02 140.86 141.00 32.06 32.00 372.75 353.00 7.56 7.50 215.50 171.00 2.18 1.73 6.34 6.30 476.98 431.00 34.92 32.00 7.2863 6.9000 0.98 0.42 2.24 3.01 158.83 1.51 177.49 3.27 1.36 237.83 17.03 2.32800 2009 West Virginia Univarsity School of Medicine p. 55